EXPORT BUSINESS SETUP

PROJECT REPORT 2023

Client: Drugs and Devices Pharma Ltd Address: S-101, Dream Heights, Pardi Vapi, Valsad - 396191, Gujarat, India Contact: 09867206448

PREPARED BY:

CYCLONE PHARMACEUTICALS PVT LTD BUSINESS CONSULTANT Authored by: SACHIN BHALEKAR





INDEX/TABLE OF CONTENT

Sr No.	PARTICULARS	Page No
1	Project Introduction	03
2	Global Pharma Market Introduction	05
3	Export Business Division	09
4	Project Budgeting /Finance Plan	11
5	Business Plan with Requirement	12
6	How to Start	14
7	Product Portfolio	20
8	Erectile Dysfunction Drugs Market Trends	23
9	Regulatory Requirements	39
10	Country Wise Regulatory Details	43
11	Example Profit Portfolio	146
12	Steps to start	147
13	Advertisement Plan	148
14	Manufacturer Selection	150
15	Other Business to be added	151
16	Procedure to Follow after receiving enquiry	153
17	Investor Presentation Content	154
18	Reports	155

Total Pages 162

<u>1.0 PROJECT INTRODUCTION</u> Drugs and Devices Pharma Pvt. Ltd.

I.INTRODUCTION:

Drugs and Devices Pharma Private Limited is one of the most trustworthy business entities in the pharmaceutical industry operating its business from Mumbai and Dubai which are financial capitals of India and the world because we offer a quality assured range of quality pharmaceutical products, nutraceutical products, surgical range of product and especially products of sexual wellness products.

With the vision of Marketing and Supplying products in Indian as well as in the global market company has established its operation offices in Mumbai and Gujrat and expanding its business wings globally.

Vision :

Drugs and Devices Pharma is willing to be a Quality Medicine manufacturing and Exporter company to cater to mankind and Humanity

Quality Policy :

The company is bound to business and Quality Ethics and will always engage in fair business practices as well as company is Quality-driven as per global quality Norms

II. PROMOTERS:

Drugs and Devices Pharma is a Partnership Firm. The Partners of the Unit are:

1. Mr. Wasim

2. Mr. Kazi

All the partners are young and dynamic and are already engaged in a similar line of business. Further, all the partners are financially sound and are capable of putting their stake in the business.

III. Project Description:

D&D Pharma is willing to spread its wings all over the world with brand-building quality

Pharmaceutical Products. Products will be mostly manufactured in India and some parts of Europe.

Targeting the Regulated Countries D and D Pharma is willing to grow its wings to the rest of the world market also.

UAE is the base for D and D Pharma and has its operations also in UAE in the nutraceuticals and Surgical segment D Pharma has served humanity and mankind during the pandemic, it has launched its Vitamin Supplement products as well as some Pharmaceutical products during the COVID-19 Pandemic situation to serve COVID Patients.

Vision Towards Specialty Segment :

D And D Pharma has the vision to build a portfolio in the specialty segment with brand building in the same.

Vital Nutrition and **Sexual well-being** with a Great brand Building is the focus of D and D Pharma along with this Anticancer, Protein supplements the another segment and then the rest of the medicine supplies

2.0 GLOBAL PHARMA MARKET INTRODUCTION

Industry Scenario

The pharmaceutical industry in India is expected to reach \$65 Bn by 2024 and \$130 Bn by 2030.

The pharmaceutical industry in India is currently valued at \$50 Bn.

India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. India supplies over 50% of Africa's requirement for generics, \sim 40% of generic demand in the US, and \sim 25% of all medicine in the UK.

India also accounts for ~60% of global vaccine demand and is a leading supplier of DPT, BCG, and Measles vaccines. 70% of WHO's vaccines (as per the essential Immunization schedule) are sourced from India.

The pharmaceutical export business is an evergreen and profit-making business. Post covid there are many opportunities available in India's Pharma Export Sector

Pharma export stood at USA \$ 2514 Billion in FY 2022-23

New entrants shall start from Non-Register Country and Product where there won't be a huge movement involved

Category-wise exports during the last three year


Product Category	2019-20	2020-21	2021-22	% Growth
Drugs Formulations & Biologicals	15948.83	19042.17	19021.05	-0.11
Bulk Drugs & Drug Intermediates	3867.77	4429.70	4472.05	0.96
Ayush & Herbals	428.07	539.88	612.83	13.51
Surgical	458.79	432.29	512.86	18.64
Grand Total	20703.46	24444.03	24618.78	0.71

Region-wise exports during the last three years

Top 25 export destinations of India's pharmaceutical products

Region	2019-20	2020-21	2021-22	% Growth
NAFTA	7258.60	8392.84	7820.77	-6.82
EUROPE	3574.36	4234.59	4426.61	4.53
AFRICA	3213.86	3917.90	3856.27	-1.57
LAC	1227.99	1447.66	1710.25	18.14
ASEAN	1292.65	1462.00	1761.01	20.45
WANA	1034.02	1320.44	1335.73	1.16
SOUTH ASIA	1167.69	1238.02	1300.48	5.05
CIS	905.27	1177.96	1097.89	-6.80
NEA	684.07	823.98	803.03	-2.54
OCEANIA	344.94	428.23	466.21	8.87
UNSPECIFIED	0.02	0.41	40.52	9782.93
Grand Total	2070	2444	2461	0.71

Rank	Country	2019-20	2020-21	2021-22	% Growth
1	USA	6749.60	7718.80	7101.60	-8.00
2	UK	557.89	716.52	704.51	-1.68
3	SOUTH AFRICA	612.01	833.53	612.30	-26.54
4	RUSSIA	552.41	590.69	597.81	1.21
5	NIGERIA	443.09	573.17	588.59	2.69
6	BRAZIL	473.10	525.28	580.78	10.57
7	GERMANY	504.17	575.47	528.30	-8.20
8	FRANCE	319.50	412.81	512.20	24.08
9	NETHERLAND	321.05	375.18	460.08	22.63
10	BELGIUM	297.18	370.19	449.77	21.50
11	CANADA	334.54	441.77	418.57	-5.25
12	AUSTRALIA	274.10	346.73	386.90	11.58
13	CHINA P RP	287.97	371.31	343.76	-7.42
14	PILLIPIN	263.99	284.40	342.25	20.34
15	KENYA	275.55	282.79	341.37	20.72
16	U ARAB EMTS	203.13	321.64	333.77	3.77
17	MYANMAR	224.75	234.57	329.95	40.66
18	NEPAL	247.26	231.32	320.12	38.39
19	BANGLADESH	250.95	261.43	309.12	18.24
20	MEXICO	159.96	212.43	287.61	35.39
21	TURKEY	216.57	295.24	282.48	-4.32
22	VIETNAM	223.76	243.90	269.05	10.31
23	TANZANIA	218.35	262.62	260.00	-1.00
24	INDONESIA	107.16	158.51	253.32	59.82
25	PAKISTAN	124.71	152.32	243.36	59.77



Source: DGCI&S; *Until February 2023



India's drug and pharmaceutical export trend (US\$ billion)

3.0 Export Business Division of D and D Pharma :

This project report is directed towards opening the Export Business division of D and D Pharma.

- I. Basic Requirements (Statutory Requirement):
 - a. Company Registration
 - b. Wholesale Drug Sales License
 - c. IEC Code
 - d. Pharmaxel Registration
 - e. Shop Act License
 - f. GST Registration

II . Office Setup:

- a. Office Establishment in Mumbai
- b. Furniture and basic office requirements with Staff

III. Company Portfolio :

- a. Company Boucher
- b. Company Website
- c. Company Visiting Cards of Concern Staff and Management
- d. Product Portfolio
- e. Product Moc Photos
- f. Company Website
- g. Company Email IDs

IV. Manufacturing and Exports

- a. Contracts with Manufacturers
- b. WHO Manufacturing Units are preferred and mandatory for Export
- c. Similar Product presence in India for company Trust and Identity

Requirement for Domestic Marketing :

- I. Basic Requirements (Statutory Requirement):
 - g. Company Registration
 - h. Wholesale Drug Sales License
 - i. Shop Act License

j. GST Registration

II. Office Setup:

- c. Office Establishment in Mumbai
- d. Furniture and basic office requirements with Staff

III. Company Portfolio :

- h. Company Boucher
- i. Company Website
- j. Company Visiting Cards of Concern Staff and Management
- k. Product Portfolio
- 1. Product Moc Photos
- m. Company Website
- n. Company Email IDs

IV. Manufacturing and Exports

d. Contracts with Manufacturers

Checklist For Ready Reference - For Client Reference

Sr No	Checkpoint	Status
1	Office Establishment in Mumbai	
2	Furniture and basic office requirements with Staff	
3	Company Boucher	
4	Company Website	
5	Company Visiting Cards of Concern Staff and Management	
6	Product Portfolio	
7	Product Moc Photos	
8	Company Website	
9	Company Email IDs	
10	Contracts with Manufacturers	
11	WHO Manufacturing Units are preferred and mandatory for Export	
12	Similar Product presence in India for company Trust and Identity	
13	Distributor Network for Domestic	
14	Logistic Arrangements Export /Domestic	

4.0 Project Budgeting /Finance Plan

Approximate Budget Considering Complete Launch of Project :

Sr. No.	Particulars	Amount
1.	Office Setup: Furniture /Computers /	15,00,000.00
	Working Expenses :	
2.	Staff Salaries Approx. Per Month 125000.00 Total Provision for Six Months	7,50,000.00
3.	Traveling Expenses for Business Per Month 75000.00 (Six Months)	4,50,000.00
4.	Stationary and Advertisement	5,00,000.00
5.	Exhibitions and Other Portal Advertisement	15,00,000.00
6.	Product Launching Cost	2,00,000.00
7.	Product Manufacturing First Batch Approx. 5000 Strips or Units Per Product Total Average 10 Products	15,00000.00
8.	Regulatory Dossier Expenses 10 Products Per Product 25000.00	2,50,000.00
9.	Audit Expenses if Triggered For Semi-Regulated Countries Approx. 3 Countries	15,00000.00
10.	BA BE Studies as Actual for Approx. 3 Products Per Product Ranging from 2500000 to 4500000 Per Product	1,20,00,000.00
	Total Approximate Project Cost Cost For Six Months Projection After that Business Must be Self-Sustained	2,01,50,000.00
	Without BA BE Studies Consideration	81,50,000.00

5.0 Detailed Business Plan with Requirements :

1. Business Plan :

- a. Objective :
 - i. To establish an export division of D&D Pharma and spread product marketing To Different countries
 - ii. To establish a company brand in UAE and surrounding countries with a vision of financial growth and a stable product portfolio

b. Targeted Market Product Segments:

- a. First Phase:
- 1.1. Allopathy brand-building products

1.1.1 Erectile dysfunction products.

- a) Sildenafil Citrate Tablet all strengths
- b) Sildenafil Gel all flavors.
- c) Tadalafil Tablet
- d) Tadalafil Gel.

2. Nutraceuticals Product Segments

This is the easiest way to start a business as this product does not require a strong registration process. The Nutra segment is nowadays the most trending segment because the major population is shifting towards natural remedies and so on, the products are in high demand. Especially the diabetic and weight loss segments are more popular in the world market.

Margins and profit are more in the Nutra segment as compared to the other Pharmaceuticals. It does not require a major licensing process or it has simple licensing requirements and world wide countries worldwide have very simple documentation.

As nutraceuticals are being considered as high value and non-decided-cost products, because these products are proprietary brands and do not have any price prediction, according to our advertisements we can convenience clients for any to, as per our quality.

3. Other Medicines -

Other segments can be penetrated according to the requirements of clients, but the medicine sector needs to have registration in almost all countries. It is divided into:

Non-regulated (non-audited) countries

- 1) Semi-regulated countries
- 2) Regulated countries

Non Regulated Market

Non-regulated countries' rates are comparatively low but the company can achieve volume. Comparatively semi-regulated and regulated countries have good profit margins and significant product prices are there.

These markets are where it is easy to register any product or there is no registration required. But comparatively, non-developed or under-developed countries have lower margins available as the income or paying capacity of the public is less. Mostly, in such countries, the government is only responsible for the fulfillment of medical needs and so most needs of such countries' imports are through a government tendering system. A lower profit with high-volume business strategies will always work for this market.


Requirements-:

Basic documentation and only WHO-approved manufacturers can export to these countries

Semi Regulated Market-

These markets are comparatively stringent market specials where product registration Criteria are applicable and they require extensive and lengthy documents.

6.0 HOW TO START (FLOW CHART)



6.1 Office Setup:

Need to set up an office with the business development team and accessible From the nearby airport or public transport for pharma business physical address Is necessary.

This is not mandatory that the office be in Mumbai or India it can be anywhere in the world. Preferable locations are near to pharma manufacturing hub.

6.2 Selection of Staff :

One or two preferably ladies/female staff shall be appointed with good Communication, good personality, dynamic presentation approach preferred Pharma background will have drug knowledge.

6.3 Staff Training:

Staff training shall be done on bellow topics by professional trainers.

- 1) Searching pharmaceutical/ medicine or distributors in different countries of the world.
- 2) Reaching to different importers.
- 3) Preparing and launching different portals like LinkedIn and others for product and company

promotion.

- 4) Reminder to different clients and importers.
- 5) Organizing meetings, presenting company.
- 6) Attending different pharma meets and pharma exhibitions around the world.

6.4 Job profile or job description for business development staff

Skill requirement:

- Good communication skill
- Good presentation skill
- Good personality
- Positive attitude
- Basic knowledge of the pharma industry

Job Description:

• Searching emails and contact details of importers of different countries.

- Promote the company and company brand in different parts of the world.
- Communication with clients.
- Follow-up for orders.
- Discussion and posting of company portfolio on different portals.

6.5 Hiring of technical staff:

- 6.5.1 Pharmaceutical export required to have thorough product knowledge and technical aspects, pharmaceutical aspect of the product which is the most important part.
- 6.5.2. For the above purpose company needs to hire technical staff who knows
- 6.5.3. Pharma and regulatory basics.
- 6.5.4 Understanding regulatory aspects, and guidelines of all countries where we
- 6.4.5 Promotes our product is again an important part of the export business.
- 6.4.6 Technical and regulatory co-ordination must know about the formats an

6.5 HOW TO START:

Domestic Existence:

This is most important to build a domestic existence in the Indian market, building a brand in the Indian market always supports revenue generation and also builds trust in the overseas client about the company.

Easy way to start:

1) Nutraceutical product-

Nutra is the easiest way to start operations because the manufacturing cost is less and it is always supportive to have some brands in our hand for sampling or showcasing purposes.

Features of Nutra products:

- 1) Less manufacturing cost
- 2) High MRP or rates as there is no price cap.
- 3) Some products can be launched in the export market as well.

Product segments to launch in Nutra:

- 1) Weight loss
- 2) Diabetes
- 3) Hair loss products
- 4) Skin glow products

2) Cosmetics product:

Cosmetic is another segment that can be manufactured and exported without major formalities. The cosmetic sector is easy to launch in any country and does not have major registration drawbacks; if a company does not have a public advertising network the cosmetic market can not generate big orders and may fail, but for brand-building purposes cosmetics is a good segment.

3) Drug Products :

The company can start its Export Business with the drug Product segment. All formulations in different drug categories can be launched and can be exported to different countries. This segment requires registration of every product in every country as well as there shall be proper marketing partners, importers, or distributors to sell these products

4.0 Immediate Starting Advice :

D and D Pharma can start bellow product segments with immediate effect:

4.1.0 Domestic Market segment : This is advised to launch a domestic division for company survival and company working expenses compensation

As discussed and as per the management vision of D& D Company is willing to go ahead with the Sexual wellness sector as a brand-building activity

4.1.1 Scenario of Indian Market :

In India, there is huge competition and the business of pharma especially for public demand or counter-sale products.

Launching with the following Portfolio is helpful for expected recovery and for brandbuilding purposes.

- Sildenafil Tablet 50/100 mg Packing 1 x4 Design shall be attractive Approx. Profit Earning ratio will be 20-25%
- Tadalafil 10/20 mf Packing 1 x 4 Similar to Pfizer Packing Approx. Profit Earning ratio will be 20-25%
- Protein Powders for Children and Adults as Meal Replacements Approx. Profit Earning ratio will be 30-45%

7.0 Product Portfolio (Trending Product for Export Business)

FINISHED FORMULATION

Product	Strength
GASTROLOGY	
Omeprazole + Domperidone Capsule	20/40 mg
Ondansetron Tablet	4/8 mg
Pantoprazole – Tablet	40
Rabeprazole Sodium Tablet	10/ 20/ 40 mg
Magnesium Tablet	400 mg
Fexofenadine HCl Tablet	8.4/5/10
Loratadine Tablet	5/10 mg
ANALGESIC & ANTISPASMODIC	
Albendazol Tablet	400 mg
Itraconazole Tablet ANTI DIABETICS	100/200 mg
ANTI DIADETICS	
Dapagliflozin Tablet	10 mg
Metformin Tablet	500/850/1000 mg
Pioglitazone HCL Tablet	15/30 mg
ANTI-BACTERIAL	1
Azithromycin Tablet	100/250/500 mg
Azithromycin dry sup Suspension	200/ 5ml
Clarithromycin Tablet	250/500mg
Clindamycin Capsule	150 /300 /600 mg
Doxycycline Tablet	100 mg
Erythromycin Stearate Tablet	200 mg/500 mg
Gatifloxacin Tablet	200/400 mg
Levofloxacin Tablet	200/500 mg

CARDIOVASCULAR DRUGS		
Amlodipine Tablet	5/10 mg	
Atrovastatin Tablet	10/20 mg	
Clopidogrel Tablet	75mg	
Clopidogrel+ Aspirin Tablet	75+75 mg	
Fenofibrate Tablet	145/160/200mg	
Irbensartan Tablet	150/300 mg	
Lisinopril Tablet	5/10 mg	
Irbensartan+Hydrochlorothiazide Tablet	125 mg	
Ivabradine Tablet	5/7.5 mg	
Lisinopril Tablet	50+12.5 mg	
Losartan Potassium Tablet	25/50mg	
Rosuvastatin Tablet	20/40 mg	
Simvastatin Tablet	5/10/20 mg	
Telmisartan Tablet	20/40/80 mg	
Valsartan Tablet	80/160/320mg	
CNS ANTIPSYCC	OTIC	
Betahistine HCL - Tablet	8/16/24 mg	
Citicoline - Tablet	500 mg	
Escitalopram - Tablet	10/20 mg	
Gabapenti – Tablet	300/600 mg	
Paroxetine – Tablet	250/500mg	
Vigabatrin – Tablet	50 mg	
ANTI MALARIA	AL	

20+120/40+240/ 80+480mg 60 ml
60 ml
160+320 mg
40+320
80
7.5/15mg
300+375/600+750
100/400/250/500mg
40/80 mg
1/5 mg
400/800 mg
400/500 mg
400 mg
500/1000 mg
500/1000 mg
500/65 mg
50/100 mg
500/1000 mg
50/100 mg
50+60 mg
10/20 mg

Sildenafil - Tablet	100 mg
Sildenafil – Jelly	100 mg
Sildenafil - Dispersible	100 mg
Sildenafil - Chocolate	100 mg

8.0 Erectile Dysfunction Drugs Market Trends

Erectile Dysfunction (ED) Drugs Market 2024-2028

The global erectile dysfunction (ED) drugs market size is estimated to grow by **USD 1.44 billion** at a **CAGR of 6.67%** between 2023 and 2028.


The awareness of erectile dysfunction is growing across the world as it is an underdiagnosed and undertreated disorder. To overcome the lack of awareness regarding the conditions that lead to ED, several organizations, healthcare agencies, and government bodies are focusing on improving the quality of life of the patients. Furthermore, there are several erectile dysfunction support groups, under which patients are provided with information on personal experiences, the side effects of drugs, the dosage forms to be taken, information on the mechanism of action, and the half-life of the drugs used for the treatment of ED. Hence, the rising awareness of ED will fuel the growth of the market during the forecast period.

The Viagra (Sidenafil citrate) Segment is Expected to Dominate the Market

Erectile dysfunction is treated with the drug sildenafil. It helps men get an erection by increasing blood flow to the penis. Viagra is the most common drug used as first-line therapy in the treatment of erectile dysfunction. Viagra is also used to treat pulmonary arterial hypertension, which causes ED. According to an article published by Hims & Hers Health, Inc., in June 2021, more than 95% of erectile dysfunctional males who used sildenafil said they were satisfied with the way it affected their erections.

Furthermore, according to an article published by Inverse, in February 2020, Sildenafil is a popular option for men seeking to treat erectile dysfunction as it helps erections last for three to five hours after taking the medication. Sildenafil is sold under the trade name Viagra, which is highly well-known and earns its parent company, Pfizer, an estimated USD 1.8 billion annually.

Therefore, the above-mentioned factors are expected to drive segmental growth in the market during the forecast period.



Physical Cause of Erectile Dysfunction (in Percentage), United States, 2021


North America is Expected to Dominate the Market over the Forecast Period

North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED, and the presence of better healthcare infrastructure. According to the September 2022 published article by MSD Manuals, in the United States, about 50% of men 40 to 70 years of age are somewhat affected by ED, and the percentage increases with aging.

Furthermore, as per an article published by the National Institute of Diabetes and Digestive and Kidney Diseases, in 2021, ED affected approximately 30 million men in the United States. Besides, the country has the highest rate of self-reported ED which is expected to drive market growth over the forecast period.


Furthermore, key drugs for ED, including VIAGRA and CIALIS, have faced patent expiration in countries such as the US and Canada. In addition, the US is a developed country, and the economic status of the population is favorable. Thus, they opt for such expensive alternative modes of treatment. The genericization and the increased adoption of alternative treatments are leading to the decelerating growth of the erectile dysfunction drugs market in North America during the forecast period.


Moreover, studies and product launches for the effective treatment of ED are also contributing to the market growth. For instance, in January 2022, Petros Pharmaceuticals, Inc., initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). Furthermore, in September 2022, Lupin Limited launched Sildenafil for oral suspension, 10 mg/mL, having received approval from the US FDA. Such advancements are driving the market.



The market for erectile dysfunction treatments is expanding as a result of an increase in the number of individual with erectile dysfunction. Throughout the projection period, market participates are anticipated to become more knowledgeable about erectile dysfunction treatment. Nevertheless, one of the primary issues projected to limit the growth of the erectile dysfunction market is the high cost of penile implants.

US Erectile Dysfunction Market is poised to grow at a sustainable CAGR for the next forecast year.





Global Erectile Dysfunction Market Segmental Analysis


The global erectile dysfunction market segmentation is based on product, and region. Based on product the Erectile Dysfunction Market is segmented into Viagra, Cialis, Zydena, Levitra, Stendra, and others. Based on region the global erectile dysfunction market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Erectile Dysfunction Market Analysis by Product

In 2021, the category selling Viagra had the biggest revenue share at 57.8%. Many business are currently engaging in a variety of strategic activities to grow their market share, including research alliances, agreements, and partnerships.

Due to the wide application base and accessibility of ED medications like Helleva (lodenafil carbonate), Mvix (mirodenafil), and others that are also used to treat adult patients with erectile dysfunction, the other segment is also anticipated to experience profitable market growth over the forecast period. Increased acceptable of over-the-counter ED medications gives patients easy access. Therefore, the release of such goods could increase the use of ED medications.

Global Erectile Dysfunction Market Share by Grade Product, 2021 (%), 2021 (%)



Global Erectile Dysfunction Market Competitive Landscape

Key market participants in the erectile dysfunction (ED) drugs market are strengthening their market positions by implementing a variety of strategies, including mergers and acquisitions and research partnerships with other business, to introduce novel products and solidify their market positions globally. For instance, due to a production error, Sun Pharmaceutical Industries Ltd. announced the recall of their generic medicine Tadalafil in November 2021. A small gap in the availability of generic ED medications used to treat erectile dysfunction patients may result from this recall.

Erectile Dysfunction Market Top Players Company Profiles

- Pfizer Inc.
- Eli Lilly and Company
- Bayer AG
- VIVUS, Inc.
- Dong-A ST Co. Ltd.
- Meda Pharmaceuticals Inc.
- S.K.Chemicals Co.Ltd.
- Teva Pharmaceutical Industries Ltd.
- Endo International plc
- Futura Medical plc
- Apricus Biosciences, Inc.
- Medtropic plc
- Coloplast Corp.
- Boston Scientific Corporation
- Zephyr Surgical Implants
- Urologix, LLC
- American Medical Systems, LLC
- Pos-T-Vac Medical

Erectile Dysfunction Market Recent Development

- In August 2022, Lupin launched an oral drug named sildenafil for erectile dysfunction in the United States.
- In May 2022, Aspargo Laboratories, Inc. purchased the prescription brand Bandol from the Spanish speciality pharmaceutical company Laboratories Rubio S.A. Bandol is used to treat patients with ED problems.
- In March 2022, the US FDA permitted Lupin to commercialize a generic version of Revation from Viatris Specialty LLC. Lupin's ANDA for sildenafil (10 mg/mL oral suspension) gained this approval.
- In February 2022, Tadalafil MAXON was first approved for marketing authorization by a Polish business, Adamed, under the OTC (over-the-counter) category.
- In January 2022, for its STENDRA erectile dysfunction (ED) medication, Petros Pharmaceuticals Inc., a provider of pharmaceuticals for men's health, started two selfselection trails (avanafil).

Erectile Dysfunction (ED) Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.

Key Erectile Dysfunction (ED) Drugs Market Drivers

Rising demand for ED drugs is the key factor driving market growth. With the rising health consciousness across the world, there has been a significant increase in healthcare spending for sexual wellness. As a result of this, there has been a surge in the demand for drugs for the treatment of disorders such as ED. This demand is arising not only due to the OTC availability of drugs but also because of the increase in the number of prescriptions for ED. Owing to the availability of treatment guidelines, physicians are using drug therapies for the treatment of ED. Furthermore, the therapeutic benefits of drugs, such as a longer half-life in the body and the ease of administration even via the sublingual route, are expected to drive the adoption of ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are also expected to drive the growth of the global erectile dysfunction (ED) market during the forecast period.

Significant Erectile Dysfunction (ED) Drugs Market Trends

The presence of novel drug formulations in late stages of development is the primary trend shaping market growth. The market is dominated by the oral formulations of the drugs used for the treatment of ED. However, in the next five years, several novel formulations of ED drugs, such as topical gels, injectables, and suppositories, are expected to emerge in the market. These novel formulations will attract a large number of patients owing to their therapeutic benefits. They are also expected to widen the scope of treatment for ED.

Moreover, for instance, the MonoSol Rx tadalafil oral soluble film by Adamis Pharmaceuticals is currently in the pre-registration stage of evaluation for the treatment of ED. The drug is the first sublingual formulation and is the first film alternative to the oral tablets available for the treatment of ED. Thus, such developments are expected to propel the growth of the global erectile dysfunction (ED) market in focus during the forecast period.


Major Erectile Dysfunction (ED) Drugs Market Challenges

Availability of generics is a challenge that affects market growth. The entry of generic drugs has resulted in hampering the revenue growth of the global ED drugs market. For example, the generic version of VIAGRA, such as sildenafil citrate, is approved by the FDA. Other generic drugs for erectile dysfunction include Avanafil, Tadalafil, and Vardenafil, which is also commercially available. The sales of Viagra have declined in recent years.

Moreover, the decline in sales of Viagra led to a decline in the market share of Pfizer, which impacted the revenue generation for the company. Also, the low cost of generics is the second major cause of the decline of the market. Generic versions of Ed drugs can be obtained at a minimal price. Hence, the availability of generics in the market will act as a challenge to the growth of the global erectile dysfunction (ED) market during the forecast period.

Key Erectile Dysfunction (ED) Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.



Global Erectile Dysfunction Market Dynamics

- Diabetes, obesity, and cardiovascular disease are on the rise due to the rise in the adoption of an unhealthy lifestyle, which in turn causes issues like ED as people age. Young people's current lifestyles are particularly stressful in many emerging nations, which has led to an increase in fast food and ready-to-eat food consumption as well as drinking and smoking. These variables are compromising general health and fitness, which in turn raises the risk of ED. Additionally, the number of ED patients increases along with continues to be a major driver of the worldwide erectile dysfunction medications market during the projection period.
- Major and growing pharmaceutical brands have boosted their investments in developing nations like India, China, Africa, and important Middle Eastern nations during the past couple of years. This has had a huge impact on the cost of medicine as well as the availability and distribution of medicines within the nations, both of which are anticipated to be important. The global market for erectile dysfunction medications is also anticipated to grow dramatically as a result of increased advertising investments.
- Increasing research and development activities by the market players to provide new treatments for erectile dysfunction is expected to drive the growth of the market.

Erectile Dysfunction Market Restraint

- Drugs for erectile dysfunction are primarily sold in developed and emerging economies; but, now- and middle-income countries account for a smaller portion of their sales. This is primarily a result of people's lack of understanding of these types of treatments, their limited purchasing power, and their unwillingness to incorporate them into their daily lives. The slow growth of the market is partly attributed to the negative side effects of these medications, which include headache, upset stomach, flushing, nasal congestion, visual issues, dizziness, diarrhea, and rash.
- Two significant market challenges are the increased production of generic erectile dysfunction medications and the rising accessibility of fake erectile dysfunction medications. Due to the lucrative marketing of counterfeit erectile dysfunction medications at noticeably lower prices than either patented or generic pharmaceuticals, consumers frequently opt for less expensive generic erectile dysfunction pills over more expensive blockbuster varieties.

Segment Overview

The erectile dysfunction (ED) drugs market report forecasts market growth by revenue at global, regional and country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.

- Region Outlook
 - o North America
 - The U.S
 - Canada
 - o Europe
 - The U.K
 - Germany
 - France
 - Rest of Europe
 - o Asia
 - China
 - India
 - Rest of the World (ROW)
 - Argentina
 - Brazil
 - Australia

Region- North America

Country Name	U.S.
Population	33.19 crores (2021)
Economy	Real gross domestic product (GDP) increased at an annual rate of
	4.9 percent in the third quarter of 2023.
War Zone Area	No
Potential for ED	Yes
Product	
Justification	 By utilizing ED prevalence based on administrative claims, an estimated 8.3% of insured men (10,302,540 estimated men [8,882,548 aged 18-64 years and 1,419,992 aged ≥65 years]) had a diagnosis of ED and sought ED care, out of 124,318,519 eligible US men aged ≥18 years in 2022. An estimated 17.1% of men with an ED diagnosis claim could benefit from PPI in 2022 (1,759,248 men aged ≥18 years).

Country Name	Canada
Population	3.82 Crores (2021)
Economy	GDP - \$ 2.0 Trillion
War Zone Area	No
Potential for ED	Yes
Product	

Region- Europe

Country Name	U.K
Population	6.73 crores (2021)
Economy	6.3 % in Q3 2023
War Zone Area	No
Potential for ED	Yes
Product	

Country Name	Germany
Population	8.23 crores (2021)
Economy	GDP - \$ 4.4 Trillion (nominal: 2023) \$ 5.5 trillion (PPP 2023)
War Zone Area	Yes
Potential for ED	Yes
Product	

Region- <u>Asia</u>

Country Name	China	
Population	141.24 crores (2021)	
Economy	GDP growth rate: 8.1% annual change (2021), GDP per capita:	
	12,556.33 USD (2021)	
War Zone Area	Yes	
Potential for ED	Yes	
Product		

Country Name	India	
Population	140.76 crores (2021)	
Economy	₹67.676 lakh crore (US 850 billion): (2022-23)	
War Zone Area	No	
Potential for ED	Yes	
Product		

Region- Rest of the World (ROW)

- Brazil
- Australia

Country Name	Brazil	
Population	21.43 crores (2021)	
Economy	GDP per capita: 7,507.16 USD (2021)	
	GDP growth rate: 4.6 % annual change (2021)	
War Zone Area	Yes	
Potential for ED	Yes	
Product		

Country Name	Australia	
Population	2.57 crores (2021)	
Economy	GDP per capita: 60,443.11 USD (2021)	
War Zone Area	No	
Potential for ED	Yes	
Product		

9.0 REGULATION REQUIREMENTS IN DIFFERENT COUNTRIES

Countries with No Formal Regulatory Approval Process

1. Albania	13. Burkina Faso	25. Haiti	38. Saint Kitts and Nevis
2. Anguilla	14. Burundi	26. Kiribati	39. Saint Lucia
3. Antigua and Barbuda	15. Cayman Islands	27. Central African Republic	40. Saint Vincent and the Grenadines
4. Aruba	16. Chad	28. Marshall Islands	41. Sao Tome and Principe
5. Azerbaijan	17. Comoros	29. Mauritius	42. Seychelles
6. Bahamas	18. Timor-Leste	30. Federated States of Micronesia	43. Solomon Islands
7. Barbados	19. Dominica	31. Montserrat	44. Somalia (pending regulations)
8. Belize	20. Gabon	32. Mozambique	45. Suriname
9. Bhutan	21. The Gambia	33. Netherlands Antilles	46. Tonga
10. Botswana	22. Grenada	34. Nauru	47. Trinidad and Tobago
11. The British Virgin Islands	23. Guinea-Bissau	35. Niger	48. Turks and Caicos
12. Brunei Darussalam (regulations for devices are pending in the coming year, per ASEAN membership requirements)	22. Grenada23. Guinea-Bissau24. Guyana	 36. Palestine 37. Paraguay (not yet harmonized, a member of Mercosur) 	49. Vanuatu

Semi-regulated Market: (ROW Countries):

1 . Philippines	AUDITED
2. Vietnam	AUDITED
3. Singapore	AUDITED
4. Malaysia	AUDITED
5. Thailand	NON AUDITED
6. Indonesia	NON AUDITED
7. Laos	NON AUDITED
8. Cambodia	NON AUDITED
9. Brunei Darussalam	NON AUDITED
10. Myanmar	NON AUDITED

(a) Asia (Sri Lanka, India, Bangladesh, ASEAN: 10 Countries Group -

(b) African countries

NON AUDITED
NON AUDITED
AUDITED
AUDITED
AUDITED
NON AUDITED
NON AUDITED
AUDITED
NON AUDITED
AUDITED
AUDITED

(c) Middle East countries (Gulf Co-operation Council countries)

1. Bahrain	AUDITED
2. Kuwait	AUDITED
3. Oman	AUDITED
4. Qatar	AUDITED
5. Saudi Arabia	AUDITED
6. UAE	AUDITED

(d) Latin America

1. Mexico	AUDITED
2. Brazil	AUDITED
3. Panama	AUDITED
4. Peru	AUDITED
5. Guatemala	AUDITED
6. Argentina	AUDITED
7. Chile	AUDITED
8. Dominican Republic	AUDITED

(e) CIS (commonwealth of independent states):

1. Russia	AUDITED
2. Ukraine	NON AUDITED
3. Armenia	NON AUDITED
4. Azerbaijan	AUDITED
5. Belarus	AUDITED
6. Georgia	AUDITED
7. Kazakhstan	AUDITED

8. Kirghizstan	AUDITED
9. Moldova	AUDITED
10. Tajikistan	NON AUDITED
11. Turkmenistan	NON AUDITED
12. Uzbekistan	NON AUDITED

Regulated Market:

1	USA
2	EU (UK, Germany, France, Ireland, Sweden etc.)
3	Japan,
4	Canada
5	Australia
6	New Zealand
7	South Africa

10.0 National Health Authorities/ Regulatory Bodies:

Country	Austr	alia
Regulatory Body	Therapeutic Goods Administration (TGA)	
Email ID	info@tga.gov.au.	
Website	www.tga	.gov.au
Registration Document	ICH-CTD	Format
Approx. Fee	Туре	Application Fee
	New Chemical Entity	\$51,608
	New generic product	\$19,904
BA BE Study Requirements	Adopted European guidelines for	
	biopharmaceutics studies	
Registration TimeLine	150 Working Days	
Other Information:-		
Audit Fee	a. Application audits assessment fees-	
	IVD medical devices-Class 1 and	
	Class 2 IVDs = \$7	7,387, Class 3 IVDs =
	\$22,387, Class IV	<i>i</i> = \$22,387
	b. Application audit assessment fees for	
	medical devices- \$4,350	
Guidelines		d Guideline and Nees
	guideline	

Country	P	Brunei	
Regulatory Body	Ministry of Health		
Email ID	corp.comms@moh.gov.bn		
Website	www.moh.gov.bn		
Registration Document		echnical Dossier (ACTD)	
Approx. Fee	Processing Fee	B\$200	
	Product License Fee	B\$200 B\$50	
	I Toduct License ree	Major Amendement- B\$150	
	Amendment Fee	Minor Amendement- B\$50	
	Renewal Fee	B\$250	
Data Requirements	Kenewarree	D\$230	
Data Requirements	Product Type	Data Requirements	
		E) and Biotechnological Product	
	Registered for less than 5	Parts I, II, III and IV	
	years in at least one		
	benchmark country		
	Registered for less than 5	Part I, Part II, and	
	years in at least one	Pharmacokinetic Data	
	benchmark country		
	containing existing		
	chemical/biological		
	entity(s) in a new dosage		
	form		
	Registered for more than 5	Parts I and II	
	years in three benchmark		
	countries		
	ii) Biosimilar Product*	Parts I, II, III and IV	
	iii) Generic Product	Parts I and II	
	iv) Medicinal Product	Part I, Certificate of Analysis	
	Evaluated via Abridged	(COA) of Finished Product and	
	Route	Stability Study Report of	
		Finished Product	
BA BE Study	As per ASEAN guidelines for I	Bioavailability and Bioequivalence	
Requirements	studies		
Registration TimeLine	Product Type	Days	
	NCE / Biotech / Biosimilar	336 working days	
	Products registered < 5		
	years		
	NCE / Biotech / Biosimilar	286 working days	
	Products registered > 5		
	years Consider Data la sta		
	Generic Products	286 working days	
Other Information:-			
Audit Fee	Fee= 100 (BND)		
Guidelines	ASEAN Guidelines		

Country	Brazil	
Regulatory Body	ANVISA	
Email ID	-	
Website	www.g	gov.br
Registration Document	Doss	sier
Approx. Fee	New Drugs	585,72-157,416
		beais
	Medical device	702,86 to
		49,641.20 beais
BA BE Study Requirements	ANVISA mandates that clinical sites and	
	analytical labs involved	
	in <u>bioequivalence</u> stud	
	certification by the agency per their <u>RDC</u>	
	<u>620-2022 guidelines</u> for certification.	
Registration TimeLine	Priority Review	
	Registration- 120 days, Post-Approval	
	Changes-60 days	
	Standard Review	
	Registration-365 days,	Post-Approval
	Changes-180 days	
Other Information:-		
Audit Fee	20,000 USD	
Guidelines	RDC 620-2022 ANVISA	
	an official member of t	he ICH and follows
	the ICH Guideline.	

Country	Ca	nada	
Regulatory Body	Hea	Health Canada	
Email ID	hcinfo.int	fosc@ca	anada.ca
Website	WWW	v.canad	a.ca
Registration Document	eCTD (D	ossier F	'ormat)
Approx. Fees	for Drug Registration	CA	D\$49,811-176,569
	for the Examination of a submission-Drugs for Human Use		ssion-Drugs for Human
	New active substan	ce	CAD \$ 565,465
	Clinical or non-clinical	data	CAD \$ 292,806
	and chemistry and	đ	
	manufacturing dat	a	
	Comparative stud	У	CAD \$ 65,985
	Administrative submi	ssion	CAD \$ 933
	New Drug Submissi		CAD \$ 41,917
	Efficacy and safety d		
	Abbreviated New Drug		CAD \$ 7,610
	submission and supplement		
	to an Abbreviated new drug		
	submission		
BA BE Study Requirements	Clinical or non-clinical CAD \$ 117,080		5 117,080
	data only		
	Comparative studies	CAD \$ 65,985	
Registration TimeLine	Normal time taken for r		
	Whether plant inspectio	on is ma	ndatory - Yes
Other Information:-			
Audit Fee	Facilities =		
	API CAD \$ 77		
	Finished Dosage	CAD \$	281,363
	Forms	C 4 D #	107 105
	Contract	CAD \$	107,185
	manufacturing		
Cuidalinas	organization	ino M4	$\mathbf{D}\mathbf{A}$ (CTD)
Guidelines	ICH Harmonised Guidel	me- M4	K4 (UID)

Country	Estonia	
Regulatory Body	Republic of Estonia Agency of Medicines	
Email ID	info@ravimiamet.ee	
Website	www.ravimiame	t.ee
Registration Document	eCTD Format	
Approx. Fee	Marketing authorization	applications
	Applications	State Fee (€)
	Issue or renewal of marketing authorization application (Human Medicinal Product)	n 32.00
	Application for variation of both type I and II to a marketing authorization (human medicinal product)	
	Issue of marketing authorization application (veterinary medicina product)	
	Application for variation requirin assessment - VRA (veterinary medicinal product)	g 16.00
BA BE Study Requirements	As per emea guidelines	
Registration TimeLine	180 days	
Other Information:-		
Assessment Fees	Assessment fees of Marketing Authorisation Applications for medicines for national, mutual recognition, and decentralized procedures	
	1. Stand-alone application (based on original data)	6000€
	2. Bibliographic application (well-established medicinal use supported by bibliographic literature)	6000€
	3. Fixed combination application (new medicinal product made of at least two active substances not previously authorized as a fixed combination medicinal product)	6000 € 4500 €
	4. Generic application	4500 €
	5. Hybrid Application	4500€

 A similar biological medicinal product 	4500 €
7. Application for traditional herbal medicinal product	4500€
8. Homeopathic medicinal product	4500€
9. Application for parallel import (per source Member State)	1000€
10. Informed consent application	3000€
11. Subsequent pharmaceutical form or strength containing the same active ingredient of the same future marketing authorization holder	3000€
Veterinary Medicinal Products	
1. Application for marketing authorization: full dossier	6000€
2. Application based on bibliographic data	6000€
3. Application for combination veterinary medicinal product	6000€
4. Application for generic veterinary medicinal product	4500€
5. Application for the hybrid veterinary medicinal product	4500€
6. Application for homeopathic veterinary medicinal product	4500€
7. Application for parallel trade (per source Member State)	1000€
Medicinal products for human use medicinal products: assessment fe authorization applications of dece and mutual (and subsequent) reco	es for marketing ntralized procedures

	where Estonia is participating as the concerned (CMS):	Member State
	1. Marketing authorization application	1500€
	2. Subsequent pharmaceutical form or strength containing the same active ingredient, change or addition of the route of administration of the same future marketing authorization holder	1000€
	3. Application for subsequent food- producing animal	1000€
	Assessment fees for the renewal o authorization	fmarketing
	1. Renewal of the Marketing Authorisation for national, mutual recognition and decentralized procedure (fee per one medicinal product)	1000€
	 Subsequent pharmaceutical form or strength containing the same active ingredient of the same future marketing authorization holder 	500€
Guidelines	EMEA Guidelines	

Country		India		
Regulatory Body	Cent	Central Drugs Standard Control Organization		
Email ID		dci@nic.in		
Website		Cdsco.gov.in		
Registration		CTD Dossier		
Document		1		
Approx. Fee	Division Name	Purpose Name	Fee Paid	
	Biologicals	Registration of Site (Form 40)	1500 USD for each site	
	Biologicals	Registration of Product (Form 40)	1000 US	
	Biologicals	Endorsement (Form 40)	1000 USD for each product	
	Biologicals	Import License (Form 8)	Rs 1000 for each product and	
	Cosmetics	Fresh (Form 42)	250 USD for each applied category	
	Import & Registration	Registration Certificate (Form 40)	Foreign Manufacturing premises Fee – 1500 USD	
			Registration Fee for single drug and 1000 USD	
	Import & Registration	Inspection or visit of the manufacturing premises	USD 5000/- Expenditure as may be required for inspection or visit of the manufacturing premises	
BA BE Study Requirements	Fee Payable Fo	or Licence, Permission, a	nd Registration	
	Rule	Subject	In rupees Indian National Rupee (INR) except where specified in dollars (\$)	

	21		
	21	Application for	
		permission to conduct	
-		clinical trial	
		(i) Phase I	3,00,000
		(ii) Phase II	2,00,000
		(iii) Phase III	2,00,000
		(iv) Phase IV	2,00,000
	22	Reconsideration of	50,000
		application for	
		permission to conduct	
		clinical trial	
	33	Application for	2,00,000
		permission to conduct	
		bioavailability or	
		bioequivalence study	
	34	Reconsideration of	50,000
		application of	
		permission to conduct	
		bioavailability or	
		bioequivalence study	
	45	Application for	5,00,000
		registration of	
		Bioavailability and	
		Bioequivalence study	
		centre	
	47	Reconsideration of	1,00,000
		application for	
		registration of	
		bioavailability and bio-	
		equivalence study	
		centre	
	52	Application for	5000 per product
		permission to	1 1
		manufacture new drugs	
		or investigational new	
		drugs for clinical trial or	
		bioavailability or	
		bioequivalence study	
	53	Reconsideration of	2000 per product
		application to	re produce
		manufacture new drugs	
		or investigational new	
		drugs for clinical trial or	
		bioavailability or	
		-	
		bioequivalence study	

r		
59	Application for	5000 per product
	permission to	
	manufacture	
	unapproved active	
	pharmaceutical	
	ingredient for the	
	development of	
	formulation for test or	
	analysis or clinical trial	
	or bioavailability or	
	bioequivalence study	
60	Reconsideration of	2000
	permission to	
	manufacture	
	unapproved active	
	pharmaceutical	
	ingredient for the	
	development of	
	formulation for test or	
	analysis or clinical trial	
	or bioavailability or	
	bioequivalence study	
67	Application for import	5000 per product
	of new drugs or	
	investigational new	
	drugs for a clinical trial	
	or bioavailability or	
	bioequivalence study or	
	for examination, test,	
	and analysis	
68	Reconsideration of	1000
	application for Import	
	of new drugs or	
	investigational new	
	drugs for a clinical trial	
	or bioavailability or	
	bioequivalence study or	
	for examination, test,	
	and analysis	
Requirem	ients for BE study of a new mo	lecule not approved
	ut approved in other countrie	
	plication in Form-44 duly signed	
	hority with name and designation	-
	easury Challan of Rs. 25000/- as	
Rul		
Ku		

	-	dertaking by the Principal Investigat			
		pendix VII of schedule "Y" of Drugs a opy of the approval granted to the Bl			
		SCO.	L study centre by		
		onsor's Authorization letter duly sign	ied by the		
		npetent authority on their letterhead	•		
		e study protocols.			
	-	e study synopsis			
	-	e-clinical single dose data and repeat	ed dose toxicity		
	dat		ta of		
		nical study data and published repor armacokinetic and pharmacodynami			
		realthy volunteers/patients data pub			
		rnals.	ineneu in reputeu		
	,	gulatory status of the drug.			
		mes of the countries where the drug			
		rketed (to be mentioned in the cover			
	-	ckage literature on the international	•		
		mplete Certificate of Analysis of same			
	& reference formulations) to be used in the BE study.14) In the case of multiple dose BE study adequate supporting				
	safety data should be submitted.				
		the case of Injectable preparation the	sub-acute toxicity		
	-	ould be submitted on the product of t	-		
		nerated in two species for adequate d			
		pending on the nature of the drug lik			
		rmonal preparations etc. Proper justi			
		nducting studies on healthy voluntee le/ female should be submitted.	rs/patients or		
	IIIa	le/ lemale should be submitted.			
Registration	S. No	Type of Application	Timelines in		
TimeLine	0.110	Type of Application	days		
	1a.	New Drug including Biological,	180		
	14	Medical Devices/Clinical	100		
		Trials/Global Trials/New Claims			
		in consultation with NDAC/MDAC			
	1b.	IND Applications in consultation	180		
	1 -	with IND committee	120		
	1c. 1d.	Subsequent New Drug Clinical Trial Protocol	120 60		
	10.	Amendments (if consultation of	00		
		NDAC is not required)			
	2	Fixed Dose Combination in	180		
	-				

		ormally be more than Rs. 12,000 per a rugs and Cosmetic act 1940 and rules	
		pove fee are excluding travel cost whi	
		would be charged other than this fee.	
		quiring 2 man-days. In case, if more n	
		s. 12,500 per man-day with package o	
		cluding product assessment (on site/	
		s. 20,000 per man-day for audit of ma	6
	in the Ce	ntral Government, are as under:	-
		nt authority of Ministry of Health &	
(Medical Devices)	-	e fee chargeable by notified bodies	
Audit Fee	As per th	e provisions of Rule 16 of Medical	Devices Rules,
Information:-			
Other			
		Directives	l
	10	Directives	50
	18	Report) Written confirmation of per EU	30
		receipt of Joint Inspection	
	17	BA/Be Site Approval (after	60
	16	Post Approval Changes (minor)	90
	4.6	consultation with CDL, NDAC	00
	15	Post Approval Changes (major) in	180
	14	Registration of Ethics Committee	100
	13	Registration of Cosmetics	90
	12	Export of Biological samples	45
	11	Extension of Shelf Life for Export	45
		(BA/BE) Study	
	10	Bioavailability / Bioequivalence	45
	9	Test License in Form 11	45
	8	Import License in Form 10	45
	/	CLAA in form 28/28-D/28-E/27- C etc	00
	7	Medical Device)	60
	6	NOC for from 29 (Biological and	60
	5	Rule 37 & Neutral Code	60
		Certificate	
		Product in Registration	
	4	Endorsement of Additional	120
		Import Registration of Drugs and Medical Devices	

Country	Korea					
Regulatory Body	Ministry of Food and Drug Safety					
Email ID			-			
Website			www.mfds.go	<u>o.kr</u>		
			Medical Devi	ces		
Approx. Fee	Item	Class	Service Fee)	Legal	Practical
(Medical					timefram	Timefram
Devices and					е	е
IVDs)						
	1 st device	Standard	US\$2,000		5 working	1 week
	registration	Class 1			days	
		Standard	US\$8,000		30	3 months
		Class 2			working	
					days	
		Standard	US\$10,000		65	5 months
		Class 3			working	
		Standard	US\$12,000		days	
		Class 4				
	Re-	All	US\$1,200/a	р	20	1-2 month
	registration		plication		working	
				1	days	
BA BE Study	-					
Requirements						
Audit Fee	US \$2500- US					
Guidelines	USFD	A Guidelines	6			

Country	Malaysia						
Regulatory	National F		<u>v</u>	ncy (NPRA)			
Body		National Pharmaceutical Regulatory Agency (NPRA)					
Email ID		<u>evisa@</u>	npra.gov.bh				
Website			pra.gov.my				
Registration			CTD/ ACTR				
Document							
Approx. Fee	Category of product	Processing Fees	Lab Fees	Certifications Fee			
	Pharmaceutical a) New Drug Products	RM 1,000.00	Single active ingredient: RM 3,000.00	RM 4,000.00			
	b) Biologics		Two or more active ingredients: RM 4,000.00	RM 5,000.00			
	Pharmaceutical a) Generic (Scheduled	RM	Single active ingredient: RM 1,200.00	RM 2,200.00			
	poison) b) Generic (Non- scheduled poison)	1000,00	Two or more active ingredients: RM 2,000.00	RM 3,000.00			
	Natural Product	RM 500.00	RM 700.00	RM 1,200.00			
BA BE Study Requirements	Ref: ASEAN Guideli	ine for the con	duct of Bioequiva	lence Studies			
Registration TimeLine	Types o	of Pharmaceu	ıtical	Timeline			
	New d	rugs and biolo	gics	245 working days			
	Scheduled & Not	210 working days					
	Generic drugs- No active ingredi	116 working days 136 working days					
	Generic (no	ingredients Generic (non- Scheduled Poison)					
	Natural Products a) Single active ingredient b) Two or more active ingredients Health Supplements a) Single active ingredient b) Two or more active ingredients			a) 116 working days b) 136 working days			
				a) 116 working days			

	c) Disease Risk Reduction Claims	 b) 136 working days c) 245 working days
Other Information:-		
Audit Fee	 Processing Fee: a) Payment of a processing fee of RM 5,000 application. b) The processing fee is non-refundable Inspection Fee: a) Payment of an inspection fee of RM 20,0 issuance of invoice by NPRA. 	
Guidelines	Drug Registration Guideline Document (DR Application for Registration of Pharmaceut	5 .

Regulatory Body Email ID]	Ministru	6 		
Email ID	Ministry of Health				
Email ID	(COBIERNO DE M				
	peptitionsciudadanas@saluc			<u>ud.gob.mx</u>	
Website		www.go			
Registration Document		Doss			
Approx. Fee			(Mexican Pesos)		
	Generic	1		\$82,011.99	
	New Molec			\$146,641.88	
	GMP Inspect	tion		\$96,666.39	
BA BE Study Requirements					
Registration TimeLine	Classificat	tion		of Response cal Days)	
	Generic		180 Da	iys	
	New Molecule		180 Da		
	GMP Inspection		Timeli	nes Vary	
	Request meeting v COFEPRIS New M		60 Day	'S	
	Committee				
	Receive New mole	ecule	20-40	Days	
	committee conclu	sions		-	
	after meeting				
Other Information:-					
Audit Fee	Additional Fees	Time of Response (Business day)		Fees (Mexican Pesos)	
	GMP Inspection	Timeline	es vary	\$96,666.39	
	Request meeting with the COFEPRIS New Molecules Committee	,		NA	
	Receive New molecule committee conclusions after meeting			NA	
Guidelines	ICH Harmo	onised Gui	delines		

Country	New Zealand				
Regulatory Body	Medicines and Medical Devices Safety Authority				
	(MEDSAFE)				
Email ID	medclearance@health.govt.nz				
Website	www.medsafe.govt.nz				
Registration Document	CTD Format Dossier				
Approx. Fee	New Medicines Application (NMA) Fees				
	Types of application	New Fee (\$)			
	New higher-risk medicine containing one or	106,503			
	more new active substances (NCE)	,			
	New intermediate-risk medicine –	53,251			
	prescription medicine				
	Any other new higher-risk medicine,	79,877			
	including biosimilar				
	New intermediate-risk medicine – non-	26,626			
	prescription medicine				
	New lower-risk medicine	10,649			
	Additional dose form – higher-risk medicine	53,252			
	– Grade 1 or 2				
	Additional dose form – intermediate-risk	53,252			
	prescription medicine – Grade 1 or 2				
	Additional dose form – intermediate-risk	26,626			
	non-prescription medicine – Grade 1 or 2				
	Additional dose form – lower-risk medicine	10,649			
	– Grade 1 or 2				
	New combination product – novel	70,292			
	combination of approved active ingredients				
	New combination pack containing two or	3,835			
	more currently approved products				
	New Medicines Application (Abbreviated I Process) Fees	Evaluation			
	Types of Application	New Fee (\$)			
	New higher-risk medicine containing one or	53,251			
	more new active substances (NCE)				
	Any other new higher-risk medicine	39,939			
	New intermediate-risk medicine –	26,626			
	prescription medicine				
	New Related Product Application (NRP	A) Fees			
	Types of Application	New Fee (\$)			
	New related product	5,731			
	· · · · ·				
	New Medicine Application Provisional Co	onsent Fees			
	New Medicine Application Provisional Co Types of Application	onsent Fees New Fee (\$)			

	medic		ical need)		ute a new	52,719
	medic	Provisional consent to distribute a new medicine (stock shortage) High risk other				
	medic		k shortag		ute a new	10,650
	Provisional consent to distribute a new medicine (stock shortage) Low risk			ute a new	2,130	
BA BE Study	As Per	Interna	tional Cor	nferer	ice on Harmonis	sation (ICH),
Requirements	Guidance on Good Clinical Practice (E6), and the of Good Manufacturing Practice and Good Laborer Practice guideline				· ·	
Evaluation TimeLine					r NMAs and CM	Ns
	Intern	nediate a	-	r Risk	Medicines	
			INE Medsafe	è	RFI response requested by Applicant	EAI Medsafe
	NMA	s (full)	200 da	ays	200 days ¹	120 days ²
		MAs eviated)	100 da	ays	200 days ¹	120 days ²
	Lower	Risk Me	dicines			
		INE Me	edsafe	requ	response lested by licant	EAI Medsafe
	L1	50 days	S	50 d	lays	30 days
	L2	100 day			days	60 days
	L3	150 da	ys	150	days	90 days
Other Information:-						
Audit Fee	New Zealand Based- Auditing of Non-Licensed Manufacturers – per hour, plus administration fee, plus disbursements = 186 USD per hour					
Guidelines			v Specific			

Country		Russia	
Regulatory Body	State Institute of Drugs and Good Practices		
Email ID	info@gilsinp.ru		
Website		Gilsinp.ru	
Registration Document	CTD Format		fic resemble to CTD)
Approx. Fee		and Biologica	
	-	of marketing	Around USD 135
	0	rization	(RUB 10000)
	For examina	tion of a drug	Around USD 4370
		gistration	(RUB 325 000)
	For Med	ical Devices	
	For issuing o	f marketing	Around USD 95
	authorization		(RUB 7000)
			safety examination
			state registration
			of potential risk)
	Class 1		605 (RUB 45000)
	Class 2a		875 (RUB 65000)
	Class 2b		D 1145 (RUB 85000)
	Class 3	Around USD 1	550 (RUB 115000)
BA BE Study	As per count	ry specific	
Requirements			
Registration TimeLine	Mutual Reco		ration Procedure
		Registration of	
	For Reference		210 Calendar Days
	Decentralize	d Registration	
		Registration of	
	For Reference	e State	210 calendar Days
Registration TimeLine (Medical Devices)	Registration of medical devices (stage 1 & stage 2) shall be 88 business days (58 days for registration activity exercised by RZN and 30 business days for examination conducted by budgetary institution reported to RZN)		
Other Information:-			
Audit Fee			
Guidelines	- ICH CTD Guio	deline	
Guiuciiiics			
	L		

Country	Ireland		
Regulatory Body	Health Product Regulatory Authority		
Email ID	<u>info@hpra.in</u>		
Website	www.hpra.ie		
Registration Document	Dossier		
Approx. Fee	Type Price in		
	New Application	on	
	Complex Dossier- New act	ive substance	
	National application	22,235	
	National application - each additional form (at same time)	7,785	
	National application - each additional strength (at same time)	1,110	
	Mutual Recognition - CMS	15,565	
	Mutual Recognition - CMS - each additional form (at same time)	5,560	
	Mutual Recognition - CMS - each additional strength (at same time)	1,110	
	Mutual Recognition - RMS Supplement	16,675	
	Outgoing MR Supplement - MRP applied for within 12 months of the national procedure ending	16,675	
	Additional Drug Master File submitted	4,445	
	Decentralised application – CMS	22,235	
	Decentralised application – RMS	55,590	
	Decentralised application CMS/RMS - each additional form (at same time)	7,785	
	Decentralised application CMS/RMS - each additional strength (at same time)	1,110	
	Decentralised/MR - additional RMS supplement	1,670	

where there are 15 or more	
concerned Member States	
concerned Member States	
Deduced Dession C	
Reduced Dossier- C	
National application	16,675
National application - each	7,785
additional form (at same	
time)	
National application - each	1,110
additional strength (at same	
time)	
Mutual Recognition – CMS	11,120
Mutual Recognition - CMS -	5,560
each additional form (at	0,000
same time)	
Mutual Recognition - CMS -	1,110
each additional strength (at	1,110
same time)	
Mutual Recognition - RMS	16,675
supplement	10,075
Outgoing MR Supplement -	11,120
MRP applied for within 12	11,120
months of the national	
procedure ending	4 4 4 5
Additional Drug Master File submitted	4,445
	16 675
Decentralised – CMS Decentralised – RMS	16,675
	44,470
Decentralised application	7,785
CMS/RMS - each additional	
form (at same time)	1 1 1 0
Decentralised application	1,110
CMS/RMS - each additional	
strength (at same time)	
Decentralised/MR -	1,670
additional RMS supplement	
where there are 15 or more	
concerned member states	
Reduced Dossier- St	
National application	11,120
National application - each	7,785
additional form (at same	
time)	

	National angliantian angl	1 1 1 0
	National application - each	1,110
	additional strength (at same	
	time)	
	Mutual Recognition - CMS	7,785
	Mutual Recognition - CMS -	4,445
	each additional form (at	
	same time)	
	Mutual Recognition - CMS -	1,110
	each additional strength (at	
	same time)	
	Mutual Recognition - RMS	11,120
	Supplement	
	Outgoing MR Supplement -	6,670
	MRP applied for within 12	
	months of the national	
	procedure ending	
	Additional Drug Master File	4,445
	submitted	-,
	Decentralised application -	11,120
	CMS	11,120
	Decentralised application -	28,905
	RMS	20,900
	Decentralised application	7,785
	CMS/RMS - each additional	
	form (at same time)	
	Decentralised application	1,110
	CMS/RMS - each additional	,
	strength (at same time)	
	Decentralised/MR -	1,670
	additional RMS supplement	1,070
	where there are 15 or more	
	concerned member states	
BA BE Study Requirements	As per country specific	
Registration TimeLine	150 Day	S
U		
Other Information:-		
Audit Fee	Туре	Fees
	Per day, per member of	1,825
	the inspection team	
	(expenses may be billed	
	additionally in certain	
	circumstances)	
	Part of day (per hour, per	260
	member of the inspection	• •
	team)	
	wanij	

	Inspection	500			
	cancellation/rescheduling				
	fee				
	Cosmetics				
	Inspections of cosmetic pro	Inspections of cosmetic product responsible			
	person, manufacturers and	distributors			
	Per day, per member of	1,825			
	the inspection team				
	(expenses may be billed				
	additionally in certain				
	circumstances)				
	Part of day (per hour, per	260			
	member of the inspection				
	team)				
	Audits/ Inspections of Noti				
	Device Manufacturers and Distributors				
	Audits (including Notified	1,825			
	Body) per day, per				
	member of the audit team				
	Audits (including notified	260			
	body) per hour, per				
	member of the audit team				
Guidelines	ICT CTD Guideline				

Country	USA		
Regulatory Body	US-FDA		
Email ID	FDAImportsInquiry@fda.hhs.gov		
Website	www.fda.gov		
Registration Document	Dossier		
Approx. Fee	FDA User Fee FY	2022	
	Prescription Drug User Fee	Act (PDUFA VI)	
	Applications	FY2022	
	Requiring clinical data	\$3,117,218	
	Not requiring clinical data	\$1,558,609	
	Program fee	\$369,413	
	Generic Drug User Fee Amend	ments (GDUFA II)	
	Applications	FY2022	
	Abbreviated new drug	\$225,712	
	application (ANDA)		
	Drug master File (DMF)	\$74,952	
	Biosimilar User Fee Amenda	ments (BSUFA)	
	Initial biological product	\$57,184	
	development (BPD)		
	Annual BPD	\$57,184	
	Reactivation	\$114,368	
	Requiring clinical data	\$1,746,745	
	Not requiring clinical data \$873,37		
BA BE Study Requirements	-		
Registration TimeLine	After NDA is received, FDA	-	
	decide whether to file it so it	can be reviewed.	
Other Information:-		#175 000	
Audit Fee	Domestic FDF Facility	\$175,389	
	Foreign FDF Facility	\$ 190,389	
	(i.e. Manufacture in Europe		
	or Asia)	¢ 26 4E0	
	Domestic API Facility	\$ 26,458 \$ 41 459	
	Foreign API Facility (i.e. \$41,458		
	manufacture in Europe or Asia)		
Guidelines	ICH CTD Guideline		
Guidelines			

Country	UK			
Regulatory Body	Medicines & Healthcare Products Regulatory			
	Agency (MHRA)			
Email ID	info@mhra.gov.uk			
Website	www.gov.uk			
Registration Document		TD/ Dossier		
Approx. Fee	Fees for registration of active substance manufactures			
	New applicationFeesNotes			
	New application for	£6,019	Notes	
	registration as a manufacturer of active substances	20,017	£3,457 application fee plus £2,562 assessment fee	
	Fees for registration of active substance importer or distributor			
	New Application	Fees	Notes	
	New application for	£3,845	Notes	
	registration as an importer or distributor of active substances		£1,983 application fee plus £1,862 assessment fee	
	Additional fee if the risk assessment of the initial application triggers an inspection		£640	
	Variations	-		
	Notification of	£283		
	changes (variation)			
	Inspection fee (per site if required)		£ 2,662	
	Active substance in fees	mporters or	distributors	

	A 1: .: C		C	1 0 0 0	
	Application fo	r	£	1,983	
	registration	1	64.042		
	Assessment of in		£	1,862	
	application: acti				
	substance impor	ter			
	/ distributor				
	Additional fee for		1	E640	
	the first day of				
	inspection if				
	triggered followi				
	risk-assessment	of			
	the application				
	Active substance manufacturers				
	Application for		£ 3,457		
	registrationAssessment of initial applicationAdditional fee for the first day of an inspection if triggered following risk-assessment of the applicationAssessment of the the application				
			£	2,562	
			f	E 871	
			£	E 283	
	Annual complian	ce			
	report Notification of changes				
			£	£ 283	
Clinical Trials:	Fee	T	pes of fee	Fee	
application fees	description				
	Applications		her fee	£ 3,366	
	with an IMP	-	ase 1, Full		
	dossier	and Simplified			
		IMF	-		
	Applications		ver fee	£248	
	without an IMP		ase IV, Cross		
	dossier	referral,			
			litional		
		pro	tocol		
	CT variations/			£248	
1	amendments				

	Accomment of		
	Assessment of		
	annual safety	£	248
	reports		-
Clinical investigations for	Notification of a clinical		
devices: Fees	investigation		ee
			ce
	Class I, IIa, or other than		7,472
	implantable or long-term invasive devices Class IIb implantable or long-term invasive, class III, and active implantable devices		
			15,627
Registration TimeLine	New active substances and biosimilar products –		products –
Č	The assessment proces		
	totalling 150 days with	an intervening	clock-off
	period between phase	1 and phase 2, i	f required.
	Existing Active Substances Applications – The		
	assessment process wi		
	150 days with an inter		
	between phase I and P	-	-
	<u> </u>	8	
Other Information:-			
Audit Fee	Fees for registration of active substance		
	importer or distributor		
	Inspection fee (per site if required) £2,662		
	Active substance importers or distributors: fees		
	Active substance imp	orters or distr	
	Active substance imp Standard daily rate for		
		inspection	ibutors: fees £ 2,662
	Standard daily rate for Active substance man	inspection	ibutors: fees £ 2,662 es
	Standard daily rate for	inspection	ibutors: fees £ 2,662
	Standard daily rate for Active substance man	inspection	ibutors: fees £ 2,662 es
	Standard daily rate for Active substance man Inspection	inspection	ibutors: fees £ 2,662 es
	Standard daily rate for Active substance man Inspection Inspection: fees	inspection	ibutors: fees £ 2,662 es £3,651
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection	inspection nufacturers: fe	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and	inspection nufacturers: fe	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins	inspection nufacturers: fe pections e biological	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat	inspection nufacturers: fe pections e biological factive	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of	inspection nufacturers: fe pections e biological f active ients (API),	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred	inspection nufacturers: fe pections e biological f active ients (API), assembly	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred sterile, non-sterile and	inspection nufacturers: fe pections e biological f active ients (API), assembly ections,	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred sterile, non-sterile and sites, non-routine insp	inspection nufacturers: fe pections e biological f active ients (API), assembly ections, pection,	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred sterile, non-sterile and sites, non-routine insp pharmacovigilance ins	inspection nufacturers: fe pections e biological f active ients (API), assembly ections, pection, laboratories,	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred sterile, non-sterile and sites, non-routine insp pharmacovigilance ins clinical trials, contract	inspection nufacturers: fe pections e biological f active ients (API), assembly ections, pection, laboratories, tures	ibutors: fees £ 2,662 es £3,651 Daily Rate £
	Standard daily rate for Active substance man Inspection Inspection: fees Type of inspection All GMP, GCP and Pharmacovigilance ins including: Intermediat sites, manufacturers of pharmaceutical ingred sterile, non-sterile and sites, non-routine insp pharmacovigilance ins clinical trials, contract homeopathic manufact	inspection nufacturers: fe pections e biological f active ients (API), assembly ections, pection, laboratories, tures	ibutors: fees £ 2,662 es £3,651 Daily Rate £ £3,651

	GDP (wholesale dealers including homeopathic wholesalers)	
	Full day rate	£2,662
	Reduced rate	£ 1,331
Guidelines	Country specific guideline	

Country	South Africa		
Regulatory Body	South African Health Products Regulatory Authority		
Email ID	enquiries@sahpra.org.za		
Website	www.sahpra.org.za		
Registration Document	eCTD		
Approx. Fee	Category- Human medicines, including		
	biologicals		
	In respect of the submission of an application		
	for registration of-		
	(i)New chemical entities, including	R111 000 per	
	highly technological products,	application	
	which have been processed by		
	the abbreviated registration		
	process (AMRP) (first strength,		
	first dosage form) (ii) Strengths and dosage forms	D 44 000 por	
	other than those referred to in	R 44 000 per application	
	sub-paragraph (i):	application	
	(iii) New chemical entities, new	R 208 400	
	bio therapeutics other than	per	
	vaccines (first strength, first	application	
	dosage form)	uppnoution	
	(iv) Strengths and dosage forms	R 82 000 per	
	other than those referred to in	application	
	sub-paragraph (iii)		
	(v) Biological products e.g. vaccines	R 177 000	
	(excluding new bio-	per	
	therapeutics)	application	
	(vi) Biological products e.g.	R 173 000	
	biosimilar (excluding new bio-	per	
	therapeutics)	application	
	(vii) Strengths and dosage forms	R 55 000 per	
	other than "those referred to in	application	
	sub-paragraph (vi)	D 04 000	
	(viii) Generic products	R 84 000 per	
	(pharmaceutical, analytical and	application	
	bioavailability evaluated)		
	including generic dental and radio-pharmaceutical products		
	(first strength, first dosage form)		

		D 27 000	
	(ix) Strengths and dosage forms	R 27 000 per	
	other than those referred in sub-	application	
	paragraph (vii)	D 0 4 0 0 0	
	(x) Generic products with clinical	R 84 000 per	
	data	application	
	(xi) Strengths and dosage forms	R 27 000 per	
	other than those referred to in	application	
	sub-paragraph (x)		
	(xii) Evaluation of additional	R 5000 and	
	submitted clinical data (pre-		
	registration)		
	(xiii) An application in terms of	R 37 800	
	section 15c of the Act		
	Category Veterinary medicines, including biologicals		
	In respect of the submission of an a	pplication	
	for registration of-		
	(i) New chemical entities,	R 13 900 per	
	including highly technological	application	
	products, (first strength, first		
	dosage form)		
	(ii) Generic products	R 12 700 per	
	(pharmaceutical, analytical and	application	
	bioavailability evaluated)		
	(iii) Generic products with clinical	R 13 900	
	data		
	(iv) Strengths and dosage forms	R 4 400	
	other than those referred to in		
	sub-paragraphs (i), (ii), (iii)		
	(v) Screening fee on receipt of the	R 1 800	
	application		
	(vi) Evaluation of additional	R2 800	
	submitted clinical data (pre-		
	registration)		
	Category Human medicines for which an application for registration has been submitted		
	as counterploted in section 15 of the act		
	In respect of the submission of an application		
	for registration of-		
	(i) Product submitted with clinical	R 14 300 per	
	and or toxicological data (first	application	
	strength, first dosage form)		
	(ii) Strengths and dosage forms	R 4 500 per	
	other than those referred to in sub-	application	
	paragraph (i)		

			2 6 4 0 6	
	(iii) Products submitted with n		R 6 400 per	
	clinical or toxicology data (firs	t a	application	
	strength, first dosage form)			
	(iv) Strengths and dosage form	is F	R 2 100 per	
	other than those referred to in	sub- a	application	
	paragraph (iii)			
	(v) Screening fee on receipt of	an	R 1 800	
	application:			
	(vi) Evaluation of additional	F	R2 900; and	
	submitted clinical data (pre-	1	(2)00, and	
	registration):	c	D24 700	
	(vii) An application in terms of	Ĩ	R34 700	
	Section 15C of the Act:			
Fees for Clinical Trials	(a) In respect of the submissi	on of an a	nnlication	
rees for chilled 111als	for the authorization of th			
	unregistered medicine for			
	(i) Clinical trial applica		32 400	
	(safety and efficacy)			
	(ii) Clinical trial applica	tion R	30 400	
	(Bioequivalence stu	dy)		
	(iii) Clinical trial applica	tion R	10 800	
	(Postgraduate study)			
	(iv) Any other clinical tr		5 000	
	application			
	(b) In respect of clinical trials	s amendm	ents	
	(i) Fees in respect of an	R	7 000 per	
	application for technica	l ar	nendment	
	amendments:			
	(ii) Fees in respect of an	R	4 100 per	
	application for		nendment;	
	administrative amendr		nd	
	(iii) Any other application e		350	
	for the purpose of		550	
	· ·	ial		
Deviate of the St	performing a clinical tr		-1 140	
Registration TimeLine	Approx 24 months for innova	tive produ	icts and 12	
	months for generic medicines.			
Other Information:-				
Audit Fee	Fees for inspections to assess t	he Quality	, Safety and	
	Efficacy of Medicines or Schedu			
	(a) Local manufacturing site		h (Travel	
	(a) Docar manaractar mg site		e changed)	
		unie to L	e changed)	

	(b) International manufacturing sites	R1 600/h (Travel time to be charged)
	(c) Wholesale sites	R1 600/h
	(d) Distributor sites, Local	R1 600/h
	(e) Clinical trial site, Local	R1 600/h
	(f) International clinical trial site	R1 600/h
	(g) Local pharmacovigilance inspection	R1 600/h
	(h) International pharmacovigilance inspection	R1 600/h
	(i) Desktop inspection to assess quality, safety and efficacy of medicines or scheduled substances:	R2 100
Guidelines	ICH CTD guideline	

Country	Myanmar			
Regulatory Body	Food and Drug Administration (FDA)			
Email ID	fda@mohs.gov.mm			
Website	W	<u>ww.fdamyanmar.gov</u>		
Registration Document	ACTD	(Dossier Format)		
Approx. Fee	Registration	300,000 (In Kyats) + Fees		
	Assessment Fees	(in kyats) for Lab analysis		
	Registration Fees	500,000 (In Kyats)		
	Variation of	100,000 (In Kyats) for each		
	Registration	variation		
BA BE Study Requirements	· · · · · · · · · · · · · · · · · · ·	the registration of generics		
	required	product for which BE study only oral solid dosage forms		
	 3. Comparator product Implement ASEAN selection criteria for comparator product (innovator product registered in the country, if innovator can't be identified, choice of comparator in order of preference are approval in ICH and associated countries, pre-qualified by WHO 			
	used in BE st selection crit - Conside justifica	ered acceptable if sufficient tion is provided		
	studies for – Conventio solid dosag	ideline when evaluating BE onal oral immediate release e form release oral solid dosage		
	6. Guideline to validation re	evaluate bioanalytical method port		
	7. Criteria for e validation re	valuate bioanalytical method port		

	-	ig oversea BE studies	
	- Study conducted at nationally accredited		
	BE centre		
		y reference country	
	(e.g. US, EU, Austral	ia)	
Registration TimeLine	06-12 M	onths	
	Application for renewal of	f registration shall be	
	submitted 90 days before	the validity of the	
	registration terminates.		
Validity of Registration	05 Years		
Other Information:-			
Audit Fee	a) Assessment	300000 Kyats	
	Fees		
	b) Registration	500000 Kyats	
	Fees		
	c) Variation Fees	100000 Kyats	
Guidelines	ACTD Guidelines		

Country		Philippines	S						
Regulatory Body	Food and Drug Administration Philippines								
Email ID	fdac@fda.gov.ph								
Website	www.fda.gov.ph								
Registration	ASEAN Common Technical Dossier (ACTD)								
Document			-	-					
Approx. Fee	Product Type	Product Type Application Evaluation Annua							
		Fee	Fee						
	1. New Chemical	100,000	150,000	30,000					
	Entity								
	2. Vaccines &	100,000	150,000	30,000					
	Biologicals								
	3. Innovative	100,000	150,000	30,000					
	Products and								
	Technologies								
	4. Generic								
	A. Prescription	1							
	Imported	10,000	75,000	15,000					
	Locally Manufactured5,00030,000								
	B. Non-Prescription			10,000					
	Imported	7,500							
	Locally Manufactured	3,500	20,000	-					
	5. Traditional and H	lerbal Medicir	ies						
	A. Prescription	10.000		1 - 0 0 0					
	Imported	10,000	75,000	15,000					
	Locally Manufactured	5,000	30,000	-					
	B. Non-Prescription		T 0 0 0 0	10.000					
	Imported	7,500	50,000	10,000					
	Locally Manufactured	3,500	20,000	-					
	6. Other Drug Produc		50.000	10.000					
	Imported	7,500	50,000	10,000					
	Locally Manufactured	3,500	20,000	-					
	7. Veterinary Med	icines, vaccin	es and Biolog						
	A. Prescription	10.000	75 000	15 000					
	Imported	10,000	75,000	15,000					
	Locally Manufactured	5,000	30,000	-					
	B. Non-Prescription		50.000	10.000					
	Imported	7,500	50,000	10,000					
	Locally Manufactured	3,500	20,000	-					
	Madical Derrice Drade	ata							
	Medical Device Produ	CTS							

	Risk Class	Application Fee (Per Device)	Evaluation Fee (Per Device)	Annual Fee (Per Device)	
	Class A	5,000	10,000	2,000	
	Class B	10,000	20,000	5,000	
	Class C	15,000	45,000	9,000	
	Class D (Includes	30,000	60,000	12,000	
	devices incorporating				
	medicinal/therapeutic				
	products)				
BA BE Study	As per ASEAN Guidelin		uct of Bioavailal	oility and	
Requirements	Bioequivalence Studies				
Registration TimeLine	Type of Application	/ Pathway	Timel		
	Abridged Review		Not more than day	0	
	Verification Review		Not more than	30 working	
	Post-approval changes,	/s	day	days	
Other Information:-					
Assessment Fee	Assessment Type	Fee		Note	
	1. Verification of	50,000	Per Ma	Per Manufacturing	
	GMP Standard		Site	Site	
	(EMP Evidence				
	Evaluation)	75.000	De s Ma		
	2. Quality System	75,000		nufacturing	
	Dossier (QSD) Evaluation		Site (or paymer		
	3. On-site GMP		paymen	10)	
	audit of				
	manufacturer				
	located in:				
	A. ASEAN	USD 7,00	0 Per ma	nufacturing	
	country		site		
	B. Other Asian countries	USD 10,00	00 Per ma site	Per manufacturing	
	C. Any other	USD 20,00		nufacturing	
	country	222 = 0,00	site		
	D. Listed Fee	USD 12,00		nufacturing	
	GMP conformity Asse of Drug Product	ssment Local,		ufactures	

	Assessment Type	Fee
	Application for GMP Certificate	50,000
	Domestic Manufacturing Inspection	60,000
Guidelines	ASEAN Common Technical Re	quirements (ACTR)

Country	Singapore					
Regulatory	Health Sciences Authority (HAS)					
Body						
Email ID			SA-CML@hsa	.gov.sg		
Website	w	<u>ww.hsa.gov.</u>				
Registration		ASEAN Com	mon Technica	al Dossier (ACTD)	
Document						
Approx. Fee			or Product R			
(Medical	Fees	Class B	Class C	Class D	Class D	
Devices)					with a	
					registrable	
		**••	*=00	*=0.0	drug	
	Application Fee	\$530	\$530	\$530	\$530	
	Immediate route Fee	\$950	\$ 3,180	N.A.	N.A.	
	Expedited Route Fee	N.A.	\$ 3,180	\$ 5,730	N.A.	
	Abridged Route Fee	\$1,910	\$3,710	\$6,050	\$10,400	
	Full route Fee	\$3,710	\$6,050	\$11,800	\$75,400	
	Full route (Priority Review Scheme Route 1)	\$4,220	\$6,800	\$13,400	\$N.A.	
	Full route (Priority Review Scheme Route 2)	\$5,460	\$8,800	\$17,300	N.A.	
	Annual Retention Fee for SMDR listing	\$37	\$64	\$128	\$128	
(New Drug)						
	Application	Screening	Evaluation	Evaluation	Evaluation	
	Туре	Fee	fee NDA-1	Fee NDA-2	Fee NDA-3	
	туре	ree	ice NDA-1	ree NDA-Z	ree NDA-3	

	Verification evaluation route	\$58()	\$16,900	\$16,900	\$5,830
	Abridged evaluation route	\$580)	\$11,400	\$11,400	\$5,830
	Full evaluation route	\$2,91	.0	\$82,900	\$82,900	\$82,900
(Generic Drug)						
	Application T	уре	Sc	reening Fee	Evaluation Fee GDA-1	Evaluation Fee GDA-2
	 Verificatio evaluation Verificatio evaluation (CECA sch 	route n route		\$580	\$10,400	\$5,300
	Abridged Eval Route	uation		\$580	\$4,080	\$2,330
Biosimilar Product	Application T	ype Screening Fee		reening Fee	Evaluation Fee NDA-2	Evaluation Fee NDA-3
	Verification evaluation rou	te		\$580	\$16,900	\$5,830
	Abridged Eval Route	uation		\$580	\$11,400	\$5,830
BA BE Study Requirements	-		1.			
Registration TimeLine	Turnaround T	ime (in w	VORKI	ng days)		
(Medical Device)	Registration Route	Class	B	Class C	Class D	Class D with a registration Drug
	Immediate Route	Immed upor submiss	1	Immediate upon submission	N.A.	N.A.
	Expedited route	N.A.		120	180	N.A.
	Abridged route	100		160	220	220
	Full route	160		220	310	310

	(Priority Review Scheme Route 1)	120	165		235	N.A.	
	Full Route (Priority Review Scheme Route 2)	120	165		235	N.A.	
(New Drug)			Turnarou	nd Timo			
(New Drug)	Application Typ	e	Screenin	ig (in		lluation (in rking days)	
	Verification evaluation route		50			60	
	Abridged evaluation route		50			180	
	Full evaluation rout	te	50			270	
(Generic Drug)	Turnaround Tim	e					
	Application Type		Screening (in working days)	Fir: commun (in wor day	ication rking	Evaluation (in working days)	
	Verification evaluation route	•	50	N.A		120	
	Verification evaluation route (CECA Scheme)	2	50	14	ŕ	90	
	Abridged Evaluation route	on	50	N.A	Α.	240	
Biosimilar Product	Application Typ	е	Screening (in working days)			luation (in rking days)	
	Verification evaluation route		50			60	
	Abridged evaluation route	on	50			180	
Other Information:-							
Audit Fee	GMP Conformity As						
	good manufacturin conformity assessm manufacturers of th	nent o	of overseas	July	ised Fees 2022)	s (effective 1	

	GMP Evidence Evaluation (per	\$630		
	manufacturing site)			
	Quality System Dossier (QSD) Evaluation	\$4,770		
	(per manufacturing site)			
	On-site GMP audit of a manufacturer loc	ated in:		
	(a) An ASEAN country (per	\$18,400		
	manufacturing site)			
	(b) an Asian country (outside of	\$20,400		
	ASEAN) (per manufacturing site)			
	(c) a country outside of Asia (per	\$24,400		
	manufacturing site)			
Guidelines	ASEAN Common Technical Requirements (ACTR)			

Country		Vietnam			
Regulatory Body	Ministry of Health- Drug Administration of				
	Vietnam				
Email ID	<u>cqld</u>	vn@moh.gov.v	<u>n</u>		
Website		dav.gov.vn			
Registration Document		ACTD-format			
Approx. Fee	Drug A	Authorization F	ees		
	Types of	Applicable	Applicable		
	Authorization	Fee	Fee in USD		
	Drugs (new)	VND 5.5	USD 237		
		million	approx.		
	Drugs (renewal)	VND 3	USD 130		
	million approx.				
BA BE Study Requirements	As per "Asian Guio				
	Bioavailability and Bioequivalence Studies"				
	Other Countries Bioequivalence Study				
	Acceptable- Accep				
	International BE-	A			
Registration TimeLine	Under the Vietnar	0 0			
	06 months, but in		*		
	12 months to com	plete the renew	val		
Other Information:-					
Audit Duration	The average dura				
	- large audit firm: 5 days				
	- Average audit firm: 3 days				
		udit firm: 2 days			
Guidelines	ASEAN CTD Guideline				

Country	Nami	ibia	
Regulatory Body	Ministry of Health and Social Service		
Email ID	info@nmrc.com.nail		
Website	nmrc.gov.na		
Registration Document	CTD Fo	ormat	
Approx. Fee	1. In respect of an app	lication for registration	
	of a category A med	icine-	
	(a) In respect of a medici	ine compounded in its	
	entirety in Namibia		
	(i) For new chemical enti		
	dosage forms or delivery		
	(a) per application	N\$ 3,000-00;	
	For registration	N\$ 1,000-00;	
	(ii) For an interchangeable		
	(a) Per application	N\$ 1,000-00;	
	(b) For registration	N\$ 500-00;	
	(iii) For a line extension of		
	(a) Per application	N\$ 1,000-00;	
	(b) For registration	N\$ 500-00;	
	(iv) For a medicine not re		
	subparagraphs (i), (ii), or		
	(a) per application	N\$ 1,000-00	
	(b) for registration	N\$ 500-00;	
	(b) in respect of a medicin	ne, not compounded in	
	its entirety in Namibia -		
	(i) for a new chemical entity, including novel dosage forms or delivery systems-		
		N\$ 3,500-00;	
	(a) per application	N\$ 3,500-00;	
	(b) for registration (ii) for an interchangeabl		
	medicine-	e mutu-source	
	(a) per application	N\$ 1,750-00;	
	(b) for registration	N\$ 700-00	
	(iii) For a line extension of		
	(a) per application	N\$ 1,750-00;	
	(b) for registration	N\$ 700-00;	
	(iv) for a medicine not re	. ,	
	subparagraphs (i), (ii), or (iii)-		
	(a) per application N\$ 1,750-00;		
	(b) for registration	N\$ 700-00	
	2. In respect of an applicat	ion for registration of a	
	category C medicine-		

	(a) in respect of a medicine	e compounded in its			
	entirely in Namibia-				
	(i) for a new chemical entity, including novel				
	dosage forms or delivery s				
	(a) per application	N\$ 1500-00;			
	(b) for registration	N\$ 500-00;			
	(ii) for an interchangeable medicine -	multi-source			
	(a) per application	N\$ 500-00;			
	(b) per registration	N\$ 250-00;			
	(iii) for a extension of a me	edicine-			
	(a) per application N\$ 500-00;				
	(b) per registration	N\$ 250-00;			
	(iv) for a medicine not refe	erred to in			
	subparagraphs (i), (ii), or	(iii)-			
	(a) per application	N\$ 500-00;			
	(b) per registration	N\$ 250-00;			
	(b) in respect of a medicin	e. not compounded in			
	its entirely in Namibia-	o,p op o			
	(i) for a new chemical entity, including novel				
	dosage forms or delivery systems-				
	(a) per application	N\$ 2,100-00;			
	(b) for registration	N\$ 7,100-00			
	(ii) for an interchangeable multi-source medicine-				
	(a) per application N\$ 875-00;				
	(b) per registration	N\$ 350-00			
	(iii) for a line extension of				
	(a) per application	N\$ 875-00;			
	(b) per registration (iv) for a medicine not refe	<u>N\$ 350-00;</u>			
	subparagraphs (i), (ii), or (
	(a) per application	N\$ 875-00			
	(b) per registration	N\$ 350-00			
BA BE Study Requirements		Νψ 330 00			
Registration TimeLine	170 da	.ys			
Other Information:-					
Audit Fee	For the performance of an	—			
	determine whether a prem				
	item 5 are suitable to be re				
	(a) In respect of the premises N\$ 400-00 per				
	of a manufacturer of hour				
	medicines in				

(b) In respect of the premises of a manufacturer of medicines outside Namibia	N\$ 9,000-00 per site, plus travelling and accommodation costs for two inspectors.
1. In respect of an application	on for registration of
a Category A medicine -	
(i) Screening Fee	N\$ 1 000-00;
(ii) Application fee:	N\$ 5 000-00;
(iii) Expedited registration fee	N\$ 15 000-00;
(v) For a line extension of a medicine:	N\$ 2 500-00;
(vi) Any post-registrationamendment submission(whether approved or not):	N\$ 1 500-00;
(vii) Transfer of a certificate of registration (whether approved or not):	of N\$ 700-00.
2. In respect of an application	on for registration of
a category C medicine-	on for registration of
(i) Screening Fee	N\$ 1 000-00;
(ii) Application Fee	N\$ 2 500-00;
(iii) Expedited registration fee	N\$ 7 500-00;
(iv) For a line extension of a medicine:	N\$ 1 500-00;
(v) Any post-registration amendment submission (whether approved or not):	N\$ 1 500-00;
(vi) Transfer of a certificat of registration (whether approved or not):	e N\$ 125-00;
3. In respect of any license issued in terms of section 31 of the act	N\$ 1000-00;
4. In respect of an authorisa use or sale of an unregistere	

	(a) registered outside Namibia but not registered in Namibia	N\$ 4 000-00;	
	(b) not registered at all	N\$ 6 000-00;	
	(c) not registered at all, but forming part of a clinical	N\$ 6 000-00	
	trial (d) registered in Namibia, but forming part of a clinical	N\$ 2 000-00;	
	trial for purposes of other indications		
	(e) prescribed for a specific patient	N\$ 50-00;	
	5. In respect of an application for the registration of a promises	N\$ 1 000-00;	
	registration of a premises used for the manufacturing of medicines:		
	6. For the performance of an inspection to determine whether a premises comply with		
	current good manufacturing		
	(a) in respect of the premises	N\$ 10 000-00 per	
	of a manufacturer of	site;	
	medicines in Namibia	N\$ 30 000-00 per	
	(b) in respect of the premises of a manufacturer of	site;	
	medicines outside Namibia		
	7. For the performance of an	expedited	
	inspection to determine whet	her a premises	
	comply with current good ma practices -		
	(a) in respect of the premises of a manufacturer of medicines in Namibia	N\$ 20 000-00 per site;	
	(b) in respect of the premises of a manufacturer of	N\$ 100 000-00 per site;	
	medicines outside Namibia		
Guidelines	Guidelines of Registration of M guideline	Iedicines- Own	

Country		Tanzania			
Regulatory Body	-	Tanzania Medicines & Medical Devices Authority			
	(TMDA)				
Email ID		medicines@tmda.go.tz			
Website		www.tmda			
Registration Document		Product De			
Approx. Fee	S/N	Service	Currency	Fee	
		Marketing Authorisation of Human and Veterinary Medicines (Domestic)			
	1	New or renewal application	TZS	1,000,000	
	2	Variation – Major	TZS	200,000	
	3	Variation – Minor	TZS	100,000	
		keting Authorisation of H icines and Biological Pro			
	4	New or renewal application – Non- biologicals	USD	2,000	
	5	New or renewal application – Biologicals	USD	3,000	
	6	6 Retention		300	
	7	Variation – Major	USD	1,000	
	8	8 Variation- Minor		300	
	9	Fast track registration	USD	Double the respective fee	
		Pricing of innovator medicinal products			
	10	New or renewal application for pricing	USD	200	
			L DEVICES	•	
		keting Authorisation of M nestic)	ledical Dev	ices	
	11	Class A for notification (Non –Registrable)	TZS	50,000	
	12 Class A (Registrable) TZS		100,000		
	13	Class B	TZS	200,000	
	14	Class C	TZS	500,000	
	15	Class D	TZS	500,000	
	16	Variation- Major	TZS	150,000	
	17	Variation-Minor	TZS	100,000	

	Marketing Authorisation of Medical Devices				
	(Imp	orted)			
	18	-			
		(Non –Registrable)			
	19	Class A (Registrable)	USD	500	
	20	Class B	USD	2,500	
	21	Class C	USD	2,500	
	22	Class D	USD	2,500	
	23	Spare parts and	USD	500	
		Accessories			
	24	Variation – Major	USD	300	
	25	Variation – Minor	USD	150	
	26	Retention (Registered devices)	USD	200	
	27	Retention (Notified devices)	USD	50	
BA BE Study	As ne	er Country Specific			
Requirements	115 PC	i country opeonie			
Registration TimeLine	1	.80 days for a drug to get a	pproval for r	narketing	
		authoriza		0	
Other Information:-					
	GMP Inspection and Quality Audit				
Audit Fee	S/N	Service	Currency	Fee	
		GMP Inspection	and Quality A	Audit	
		GMP inspection and Qua	lity Audit fee	for	
		medicines and medical de	evice facilitie	es per block	
		(Foreign)			
	1.	East Africa	USD	4,000	
	2.	Southern Africa	USD	4,500	
		Development			
		Community (SADC)			
		Countries			
	3.	Rest of Africa	USD	5,000	
	4.	Asia	USD	6,000	
	5.	Europe	USD	6,500	
	6.	America	USD	7,500	
	7. Australia and New USD 7,500 Zealand				
	Country Specific Guidelines				

Country	Country Taiwan			iwan	
Regulatory B			Ministry of Health and Welfare /TFDA		
Email ID	-	TFDAmethod@fda.gov.tw			
Website			www.mo	<u>phw.gov.tw</u>	
Registration Doc	ument			ssier	
U		Dossier	Requirement		
Evaluation	NDA		ANDA	OTC Monograph Drug Application	
Reference Drug	Not Requi	red	Required	Compiled with monograph	
Safety Efficacy	Pharm/PK/PD/Clinical	BA/BE	Bioequivalence (BE) as a surrogate to clinical trial		
Quality	PIC	 Chemistry, Manufacturing and cosmetic (CMC) PIC/S GMP PIC A GAP 			
Labeling		Labeling (direction of use)			
Approx. Fee for M Devices	Iedical	Registr	ation Applicati	on Fee	
		(Class I	NT \$ 3,000 (US \$ 97)	
		(Class II	NT \$ 6,000 (US \$ 194)	
		С	lass III	NT \$ 12,000 (US \$ 388)	
		С	lass IV	NT \$ 24,000 (US \$ 776)	
		Priorit	ty review date		
			Class I	NT \$ 15,000 (US \$ 1521)	
				NT \$ 30,000 (US \$ 1,042)	
		Annual	Retention Fee		
		(Class I	NT \$ 1,000 (US \$ 32)	
			Class II	NT \$ 2,000 (US \$ 64)	
		С	lass III	NT \$ 4,000 (US \$ 128)	
			lass IV	NT \$ 8,000 (US \$ 256)	
				. , , , , , , , , , , , , , , , , , , ,	
BA BE Study Requi	A BE Study Requirements As per regulation of Bioavailability and Bioequivalence Studies		availability and		
Registration Tin	neLine		ation of Generi	c Drugs Review	
			Drug (Non- covigilance)	180 days	

	Generic Drug	210 days		
	(Pharmacovigilance)			
	Active Pharmaceutical	180 days		
	Ingredients			
	Drug Master File (DMF)	180 days		
	Review Process and Tir	neline for NDAs/BLAs		
	NCE/BLA standard	360 days		
	Review			
	Priority Review	240 days		
	Abbreviated Review	180 days		
	Non-NCE (with clinical	300 days		
	data)			
	Non-NCE (without	200 days		
	clinical data)			
Other Information:-				
Audit Fee	The fee of the on-site inspection is NT\$600,000,			
	including document review (NT\$60,000) and on-			
	site inspection (NT\$540,000)			
	Each application for on-site inspection shall be			
	limited to 2 items. For th			
	apply for more than 2 items, an additional			
	NT\$35,000 will be charge			
	inspection item in the same			
	additional NT\$105,000 w	0		
Cuidelines	additional inspection iter			
Guidelines	TFDA Regulations			
<u>L</u>				

Country	Hong Ko	ng	
Regulatory Body	Department of Health		
Email ID	pharmageneral@	dh.gov.hk	
Website	www.drugoffic	<u>e.gov.hk</u>	
Registration Document	Dossier		
Approx. Fee	Fees of New Regi	stration	
	Туре	Fees	
	Application Fee	HK\$ 1,100	
	Registration Certificate	HK\$ 1,370	
	Renewal of Product	Registration	
	Renewal of Certificate	HK\$ 575	
BA BE Study Requirements	The BE studies should be	conducted in	
	accordance with the WHO) guidance	
	document.		
	"Multisource (generic) pharmaceutical		
	products: guidelines on registration		
	requirements to establish		
	interchangeability",		
	Or other international gui	idelines.	
Registration TimeLine	3-6 Mont	hs	
Other Information:-	All drugs must be registered with the		
	pharmacy and poisons Board prior to being		
	sold in Hong Kong.		
Audit Fee	-		
Guidelines	ICH CTD		

Country	UAI	8	
Regulatory Body	Ministry of Health		evention
Email ID	info@mohap.gov.ae		
Website	www.Mohap.gov.ae		
Registration Document	E-CTD Do	<u> </u>	
Approx. Fee	Туре		Fees
(Medical Device)	Application		AED 100
	Registration of a medie	cal	AED 5,000
	Device		,
(Conventional	Service	Fees	
Pharmaceutical Product)			
	Types		Fees
	Application		AED 100
	Registration of a		AED 7,000
	conventional		
	pharmaceutical product		
	Analysis or re-analysis o	of a	AED 3,500
	medical product		
	Pricing certificate after		AED 500
	committee approval		
	For PV plan evaluation A		AED 1000
BA BE Study Requirements	AED 4000-8000		
Registration TimeLine	Туре		orking Days
(Medical Device)	Registration of	45	working days
	Medical Device		
(Conventional	45 Workir	ng day	ſS
Pharmaceutical Product)			
Other Information:-			
Audit Fee	Service	1	
	Application Fee	1	AED 100
	Fees for initial inspecti	ion, a	ccording to
	the type of facility:		
	Warehouses, pharmacies		AED 1,000 per
	and scientific offices: inspection		
	Drug manufacturers and AED 3,000 per		· •
	medical devices		inspection
	Final inspection fees, a		ing to the
	type of facility:		AED 1 000 mor
	Warehouses, pharmacies		AED 1,000 per
	and scientific offices		inspection

	Drug manufacturers and	AED 3,000 per
	medical devices	inspection
	Fees for accrediting the	AED 2,000
	geometric plans for	
	factories of medicines and	
	medical devices	
	Final license fees, according to the type of	
	facility:	
	Pharmacies and warehouse	AED 7,500
	Factories of medicines and	AED 50,000
	medical devices	
Guidelines	ICH CTD	

Country		Zimbabwe			
Regulatory Body	Medici	Medicines Control Authority of Zimbabwe (MCAZ)			
Email ID	mcaz@mcaz.co.zw				
Website		www.mcaz.co.zw			
Registration Document		CTD Format			
Approx. Fee	Арг	olication for a registration of med	licine		
		case of a medicine imported into			
	Ziı	mbabwe as a finished product for	-		
	Sr. No.		USD		
	(i)	a new chemical entity including dosage form or delivery system (human)	3,000		
	(ii)	a new chemical entity including dosage form or delivery system (veterinary)	2,000		
	(iii)	a generic medicine (human)	2,500		
	(iv)	a generic medicine (veterinary)	1,500		
	(v)	a line extension of medicine (human)			
	(vi)	a line extension of medicine (veterinary)	1,000		
	(vii)	Orphan medicine	750		
	(viii	a previously registered medicine	750		
	(ix)	Submission of an application	600		
	Zin rep pro	case of a medicine imported into nbabwe and which is re-labelled o acked before being sold as finish oduct-	ed		
	(i)	Human medicine	1,500		
		New chemical entity	1,500		
	(iii)	Veterinary medicine	900		
	(iv)	a previously registered medicine	750		
	(v)	Resubmission of an application	600		
	(c) In a	any other case-			
	(i)	Human medicine	1,500		
	(ii)	New chemical entity	1,500		
	(iii)	Veterinary medicine	900		
	(iv)	A previously registered medicine	750		
	(v)	Resubmission of an application	600		

	(d)Ir	case of expedited review o	f-		
	(i)	A new chemical	4,500		
	(ii)	a generic medicine	4,000		
	(iii)	A line of extension of a	3,000		
		medicine			
	Re	tention of registered medic	ine, annually		
	In cas	e of a medicine for human use	500		
	-	ted into Zimbabwe as a finish	ed		
	produ		300		
		imported into Zimbabwe as a finished			
	produ				
		ked before being sold as finis			
		Human medicine	300		
	(ii)	Veterinary medicine	200		
DA DE Study Doquinomonto	In coo	o of a madicina imported in	to 7imhahwa		
BA BE Study Requirements		e of a medicine imported in nished product	to zinibadwe		
	(a) Bioavailability/Bioequivalence 300 USD				
	In case of a medicine imported into Zimbabwe and				
	which is re-labelled or repacked before being sold				
		uman or veterinary medicine	0		
	(i) Bioavailability/Bioequivalence 200 USD				
	Any other case-				
	(i)	Bioavailability/Bioequivaler	ce 75 USD		
Registration TimeLine	No.	Pathway	Time		
			(months)		
	1	WHO Collaborative	3*		
		Registration Procedure	C .1.		
	2	Expedited registration	6*		
	3	pathway Zazibana (SDAC) Jaint	12 (0, 2)		
	3	Zazibona (SDAC) Joint	12 (9+3)		
		Review Pathway + Country level approval			
	4	Complementary medicines	12		
	4Complementary medicines125Veterinary medicines15				
	5Veterinary medicines1560ther products18-24				
		onici producto			
Other Information:-					
Audit Fee	Inspe	ction of premises-	USD		
	(a)		re's 1,000		
	(h	*	200		
	(b) Other premises	200		

	(c)	Other premises, expedited inspection	400 plus costs of the
			re-
			inspection
Guidelines	ІСН СТ	D- Guidelines	

Country			Armenia					
Regulatory	The Scientific Canter of Drug and Medical Technologies Expertise (SCDMTE)							
Body								
Email ID			<u>lmin@pharm.a</u>					
Website		<u>v</u>	www.pharm.ar	<u>n</u>				
Registration			Dossier					
Document	Trans a f	Desisteretie	Desisteretie	Desisteretie	D			
Approx. Fee	Type of Application	Registratio n under the	Registratio n under the	Registratio n under the	Re- Reregistratio			
	Application	standard	simplified	EAEU	n under the			
		procedure	procedure	regulations	EAEU			
		or EAEU	procedure	(reference	regulations			
		regulations		country)				
		valid only						
		for the RA						
	I.A. Generic	1 100 000	500 000	2 100 000	1 000 000			
	medicinal							
	product							
	I.A.1 Each	1 100 000	500 000	2 100 000	1 000 000			
	subsequent							
	pharmaceutica l form and							
	flavouring							
	variety							
	I.A.2 Each	500 000	250 000	1 100000	500 000			
	subsequent							
	strength							
	I.A.3 Each	1 100 000	500 000	2 100000	1 000 000			
	subsequent							
	manufacturing							
	site/variation							
	Generic	800 000	500 000	1 500 000	500 000			
	medicinal							
	product with well-							
	established							
	use							
	Each	800 000	800 000	1 500 000	500 000			
	subsequent			1000000				
	pharmaceutica							
	l form and							

flavouring variety				
2. Original medicinal product, immunolog medicinal product or new combinatio	gical	1 000 000	3 500 000	1 500 000
2.1 Each subsequen pharmaceu l form and flavoring variety	2 400 000 t	1 000 000	3 500 000	1 500 000
2.2 Each subsequen strength	t 1 200 000	500 000	1 750 000	750 000
2.3 Each subsequen manufactu site/variat	ring	1 000 000	3 500 000	1 500 000
2.4 Each subsequen presentation form		50 000	80 000	80 000
3. Biosimi blood proc new combinatio of well-kno medicinal products o hybrid medicinal product	luct, ons own r	900 000	3 100 000	1 500 000
4. Veterina medicinal product	ary 800 000	500 000	1 500 000	500 000
5. Herbal medicinal product	800 000	500 000	1 500 000	500 000
6. Homeopat	800 000	500 000	1 500 000	500 000

	medicinal product						
Expertise fee f	for clinical trials		orizatio	on in th	e Re		
	Туре о	of assessment				Assessm includin (Armeni	
	Expertise for clin Republic of Arm		orisatio	n in the		-	500 000
	Expertise of biod when the invest is registered in t clinical trial or c given by the con country	igational pharm he Republic of a ompassionate u	aceutica Armenia Ise autho	al produ or has orisatio	ıct a n		250 000
	Expertise of changes in documents after obtaining clinical trial authorisation					100 000	
	Annual fee that must be paid started from next year					100 000	
Registration TimeLine			180 (days			
Other Information: -							
Audit Fee	Types of Assess	sment				t Fee, incl drams)	luding VAT
	Medicinal produ pre-licensing ins			280 00		,	
Guidelines	ICH CTD	Guideline					

Country	Latvia	
Regulatory Body	State Agency of Medicines Republic	c of Latvia
Email ID	info@zva.gov.lv	
Website	www.zva.gov.lv	
Registration Document	eCTD Dossier/ Application Do	ossier
Approx. Fee	Туре	Fees
	- Application for a new active substance	4000,00 EUR
	-Application for a medicinal product with well-established use	4000,00 EUR
	-Application for marketing authorization of a medicinal product containing an active substance used in an authorized medicinal product, but not in this combination (application for a fixed combination)	4000,00 EUR
	- Application for marketing authorisation where the marketing authorisation holder of the original medicinal product has given their approval for the marketing authorisation applicant to use pharmaceutical, non-clinical and clinical documentation included in the marketing authorisation documentation of the original medicinal product with an identical qualitative and quantitative active substance content and pharmaceutical form (Application with approval)	4000,00 EUR
	-Application for a generic medicinal product	2500,00 EUR
	-Mixed marketing authorisation application	2500,00 EUR
	 Application for expansion of marketing authorisation in accordance with Annex 1 of the European Commission Regulation (EC) No. 1234/2008 of 24 November 2008 concerning the examination of 	1500,00 EUR

	variations to the terms of marketing		
	authorisations for medicinal products		
	for human use and veterinary		
	medicinal products		
	-Application for a homeopathic or	560,00 EUR	
	anthroposophic medicinal product, 1		
	pharmaceutical form or 1 strength		
	-Application for a medicinal product	1500,00 EUR	
	with identical marketing		
	authorisation documentation, but		
	different names and one and the same		
	or different marketing authorisation		
	holder (repeat application, submitted		
	simultaneously		
	-Application for a homeopathic or	560,00 EUR	
	anthroposophic medicinal product, 1		
	pharmaceutical form or 1 strength		
	-Application for a traditional-use	560,00 EUR	
	herbal medicinal product (for herbal		
	medicinal products to be authorised		
	via the simplified marketing		
	authorisation procedure), 1		
	pharmaceutical form or 1 strength		
	Additional fee for each additional medie	cinal product	
	strength and/or pharmaceutical form, i	f submitted	
	together with the initial marketing authorisation		
	application		
	-Marketing authorisation	1000,00 EUR	
	Additional fee for performing tasks for	Latvia as a	
	reference member state in a mutual rec		
	decentralised procedure	0	
	-For marketing authorisation	8500,00 EUR	
	- For repeat use mutual recognition	2500,00 EUR	
	procedure (RUP procedure)		
BA BE Study	2000- 4000 Euros		
Requirements			
Registration TimeLine	120 working days		
Other Information:-			
Audit Fee	- First day of Inspection – EUR	1000,00	
	- The next day of each inspection- EUR		
	500,00		
Guidelines	ICH CTD Guideline		

Country	Norway		
Regulatory Body	Norwegian Medicines Agency		
Email ID	post@noma.no		
Website	www.legemiddelverket.no		
Registration Document	eCTD Dossier		
Approx. Fee	National		
	1.1 Marketing Authorisation application (national)		
	Complete dossier/well established	456 089	
	use(WEU)/fixed combinations,		
	Hybrid/Generic/Biosimilar/Informed	171 033	
	consent		
	Additional formulations and strengths	17 104	
	applied at the same time		
	Annex I: applications except new	102 620	
	formulations/strengths		
	Annex I (Line extension): new	114 023	
	formulations and strengths		
	Duplicate application (applied at the same	34 206	
	time)		
	Application for registration of a traditional	171 033	
	herbal medicinal product, with HMPC-		
	monography		
	Application for registration of a traditional	228 045	
	herbal medicinal product, without HMPC-		
	monography (upon agreement)	220.045	
	Marketing authorisation application for natural remedies	228 045	
		22 804	
	Withdrawal of application before procedure start – administrative fee	22 804	
	Variation applications and applications f	or renewal	
	(national)	0 (0 2	
	Type IB variation which leads to changes	9 692	
	in the SmPC, PL and labeling Type II variation: change in therapeutic	85 518	
	indication	03 310	
	Type II variation: change in legal status	85 518	
	Other type II variations	14 253	
	Renewal	45 609	
	Traditional herbal medicinal products:	25 654	
	type II variation – change in traditional	23 034	
	use indication		
	use multation		

· · · · · · · · · · · · · · · · · · ·	aditional herbal medicinal products:	9 692
	pe IB variation which leads to changes in	
	e SmPC, PL and labeling	
	aditional herbal medicinal products:	14 253
	her type II variations	22.004
	aditional herbal medicinal products:	22 804
re	newal	
Pa	rallel import (national)	
	pplication for marketing authorisation	18 243
	enewal	5 701
	inewai	0701
M	RP- Norway as the RMS	
	arketing authorisation application (MRP-R	MS)
	reement on RMS-ship	57 011
	itiating MRP, regardless of legal basis	114 023
	peat use, regardless of legal basis	114 023
	nex I: applications except new	102 620
	rmulations and strengths	
	nex I (line extension): new	142 527
	rmulations and strengths	
	-	
	Variation applications and applications	for renewal
	IRP-RMS)	
Ту	pe IB variation which leads to changes	12 541
in	the SmPC, PL and labeling	
Ту	pe II variation: change in therapeutic	85 518
in	dication	
Ot	her type II variations	13 683
	orksharing: change in therapeutic	85 518
	dication	
W	orksharing: type IB variation which	11 403
W lea	orksharing: type IB variation which ads to changes in the SmPC, PL and	11 403
W lea lal	orksharing: type IB variation which ads to changes in the SmPC, PL and peling	
W lea lal Re	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal	45 609
W lea lal Re Tr	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products:	
W lea lal Re Tr ty	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in	45 609
W lea lal Re Tr ty th	orksharing: type IB variation which ads to changes in the SmPC, PL and peling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling	45 609 9 122
W lea lal Re Tr ty th Tr	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products:	45 609
W lea lal Re Tr ty th Tr ty ty	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products: pe II variations	45 609 9 122 13 683
W lea lal Re Tr ty th Tr ty Tr	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products: pe II variations aditional herbal medicinal products:	45 609 9 122
W lea lal Re Tr ty th Tr ty Tr	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products: pe II variations	45 609 9 122 13 683
W lea lal Re Tr ty th Tr ty Tr ty Tr re	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products: pe II variations aditional herbal medicinal products: newal	45 609 9 122 13 683
W lea lal Re Tr ty th Tr ty Tr ty Tr r e M	orksharing: type IB variation which ads to changes in the SmPC, PL and beling enewal aditional herbal medicinal products: pe IB variation which leads to changes in e SmPC, PL and labeling aditional herbal medicinal products: pe II variations aditional herbal medicinal products:	45 609 9 122 13 683 22 804

	Complete dossier/well established	114 023
	use(WEU)/fixed combinations, Hybrid/Generic/Biosimilar/Informed	85 518
	consent,	
	Additional formulations and strengths	17 104
	applied at the same time	
	Annex I: applications except new	57 011
	formulations and strengths	
	Annex I (Line extension): New	57 011
	formulations and strengths	
	Application for registration of a traditional	85 518
	herbal medicinal products, with HMPC	
	monography	
	Application for registration of a traditional	114 023
	herbal medicinal products, without HMPC	
	monography (upon agreement)	
	Withdrawal of application before	22 804
	procedure start – administrative fee	
BA BE Study Requirements	-	
Registration TimeLine	120 Working Days	
Other Information:-		
Audit Fee	-	
Guidelines	ICH CTD Guideline	

Country		<u>D</u>	enmark	
Regulatory			edicines Agency	
Body				
Email ID		dkma	a@dkma.dk	
Website		Laegemie	ddelstyrelsen.dk	
Registration		eCT	ՐD Dossier	
Document				
Approx. Fee	Application Type	Drug Type	Boundary	Fee
	new market	Ordinary	Fully documented	DKK
	driving permit	medicines	application	327,176
	and	and vitamin/	Fixed combination of	DKK
	extensions	mineral	medicines	327,176
		preparations	Bibliographical	DKK
			applications	287,447
			Hybrid application with clinical studies regarding efficacy and /or safety	DKK 287,447
			Application concerning biologically medicine that corresponds to already approved medicines	DKK 287,447
			Application concerning vitamin and mineral preparations,	DKK 287,447
		Procedure Denmark's role- National	Hybrid application without clinical studies regarding effect and/ or security	DKK 190,538
			Generics for animals, antiotics	DKK 190,538
			Generic for humans	DKK
				189,534
			Generics for animals, not	DKK
			antibiotics	189,534
			Duplicate with same	DKK
			schedule as an application,	57,430
			where payment is made full fee	
			Parallel registration	DKK 66,960

Addition to required assessment beyond standard course due to complexity or of the submitted documentationDKK 42,648Procedure Denmark's role- DCP, RMSFiled coumented applicationDKK 378,989Procedure Denmark's role- DCP, RMSFiled combination of medicinesDKK 378,989Bibliographical application biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid application biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid application biologically medicine that corresponds to already approved medicinesDKK 241,347Generics for animals, antibioticsDKK 241,347Generics for animals, antibioticsDKK 241,347Parallel registration full feeDKK 75,633Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 241,033Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 247,033				
standard course due to complexity or of the submitted documentationLater expansion of marketing permissionDKK 181,400Procedure Denmark's role- DCP, RMSFully documented applicationDKK 378,989Fixed combination of medicinesDKK 372,689Hybrid application with clinical studies regarding effect and/ or security Application concerning biologically medicinesDKK 372,689Hybrid application concerning biologically medicinesDKK 372,689Hybrid application corresponds to already approved medicinesDKK 372,689Hybrid application corresponds to already approved medicinesDKK 243,477Generics for animals, antibioticsDKK 244,347Generics for animals, antibioticsDKK 241,347Generics for animals, nutibioticsDKK 241,347Generics for animals, antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Parallel registration regarding effect or of the submitted document smade full feeDKK 75,633Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKKAddition to required assessment beyond std. course due to complexity or of the submitted documentationDKK			Addition to required	DKK
complexity or of the submitted documentation DKK Later expansion of marketing permission DKK Procedure Denmark's role-DCP, RMS Fully documented application DKK Bibliographical application DKK MS Bibliographical application of medicines DKK Bibliographical application with clinical studies regarding effect and/or security DKK Application concerning biologically medicines DKK Hybrid application DKK approved medicines 372,689 Hybrid application with clinical studies regarding effect and/or security DKK Application concerning biologically medicine that corresponds to already approved medicines DKK Hybrid application DKK Generics for animals, antibiotics 243,477 Generics for animals, attibiotics DKK 241,347 Generics for animals, attibiotics DKK 241,347 Parallel registration DKK Addition to required assessment beyond std. course due to complexity or of the submitted documentation DKK Addition to required assessment beyond std. course due to complexity or of the submitted documentation DKK				42,648
submitted documentation Later expansion of marketing permission DKK Procedure Denmark's role-DCP, RMS Fully documented application 378,989 Bibliographical application DKK 372,689 Hybrid application with clinical studies regarding effect and/ or security DKK 372,689 Application corening biologically medicine that corresponds to already approved medicines DKK 372,689 Hybrid application of security DKK 372,689 DKK Generics for animals, application DKK 372,689 DKK Application concerning biologically medicine that corresponds to already approved medicines DKK 372,689 Hybrid application DKK 372,689 DKK Generics for animals, application DKK 372,689 Hybrid application DKK 372,689 DKK Application concerning biologically medicine that corresponds to already approved medicines DKK 372,689 Hybrid application DKK 243,477 Z43,477 Generics for animals, and antibiotics 242,602 Generics for animals, not antibiotics 242,602 Generics for animals, and file DKK Z41,347 Z41,347 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Later expansion of marketing permissionDKK 181,400Procedure Denmark's role- DCP, RMSFully documented applicationDKK 378,989Bibliographical applicationDKK 372,689Hybrid application with clinical studies regarding effect and/ or securityDKK 372,689Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK 372,689Generics for animals, autibioticsDKK 243,477Generics for animals, autibioticsDKK 244,347Generics for animals, autibioticsDKK 241,347Generics for animals, autibioticsDKK 241,347Generics for animals, autibioticsDKK 241,347Cenerics for animals, not autibioticsDKK 241,347Cenerics for animals, not <b< td=""><td></td><td></td><td></td><td></td></b<>				
marketing permission181,400Procedure Denmark's role-DCP, RMSFully documented applicationJKK 378,989Bibliographical applicationDKK a72,689Hybrid application with clinical studies regarding effect and/or securityDKK 372,689Hybrid application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK 372,689Bibliographical studies corresponds to already approved medicinesDKK 372,689Hybrid application corresponds to already approved medicinesDKK 243,477Generics for animals, attibioticsDKK 242,602Generics for animals, attibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Generics for animals, not antibioticsDKK 75,633MKK assessment beyond std. course due to complexity or of the submitted documentationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 74,103				
Proceedure Denmark's role-DCP, RMSFully documented applicationDKK 378,989Bibliographical application medicinesDKK 372,689Hybrid application with clinical studies regarding effect and/or securityDKK 372,689Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK 372,689WK applicationDKK 372,689Vibrid application corresponds to already approved medicinesDKK 243,477Generics for animals, corresponds to already approved medicinesDKK 243,477Generics for animals, antibioticsDKK 241,347Generics for animals, antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registration assessment beyond std. course due to complexity or of the submitted documentationDKK 250,046Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046			-	
Denmark's role-DCP, RMSapplication378,989Fixed combination of medicinesJKK 372,689Bibliographical applicationDKK 372,689Hybrid application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Generics for animals, antibioticsDKK 243,477Generics for animals, antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 76,034			marketing permission	181,400
Denmark's role-DCP, RMSapplication378,989Fixed combination of medicinesJKK 372,689Bibliographical applicationDKK 372,689Hybrid application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 372,689Generics for animals, antibioticsDKK 243,477Generics for animals, antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 76,034				
role-DCP, RMS Bibliographical application of DKK medicines 378,989 Bibliographical application DKK 372,689 Hybrid application with clinical studies regarding effect and/ or security Application concerning biologically medicine that corresponds to already approved medicines Hybrid application DKK without clinical studies regarding effect and/ or security Generics for animals, DKK antibiotics 2442,602 Generic for humans DKK 241,347 Duplicate with same schedule as an application, where payment is made full fee Parallel registration Addition to required assessment beyond std. course due to complexity or of the submitted documentation Later expansion of DKK			5	
RMSmedicines378,999Bibliographical applicationDKK372,689Hybrid application with clinical studies regarding effect and/ or security372,689Application concerning biologically medicine that corresponds to already approved medicinesDKKHybrid applicationDKKWithout clinical studies regarding effect and/ or security243,477Generics for animals, antibioticsDKKAttibiotics242,602Generics for animals, antibioticsDKK241,347OKKGenerics for animals, not antibioticsDKK241,347Ouplicate with same schedule as an application, where payment is made full feeDKKParallel registrationDKK 75,633Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKKLater expansion ofDKK			A A	
Bibliographical application Bibliographical application Hybrid application with clinical studies regarding effect and/ or security Application concerning biologically medicine that corresponds to already approved medicines Hybrid application Hybrid application Bibliographical poly corresponds to already approved medicines Hybrid application Bibliographical poly corresponds to already approved medicines Bibliographical poly Bibliographical studies Bibliographical studies Corresponds to already approved medicines Bibliographical studies Corresponds to already approved medicines DKK attibiotics Consecutiv Course due to complexity or of the submitted documentation Later expansion of DKK		-		
Hybrid application with clinical studies regarding effect and/or securityJKK 372,689Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid application corresponds to already approved medicinesDKK 372,689Hybrid application securityDKK 243,477Generics for animals, antibioticsDKK 244,002Generics for animals, antibioticsDKK 244,347Generics for animals, antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registration assessment beyond std. course due to complexity or of the submitted documentationDKK 20,046Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046		RMS		
Hybrid application with clinical studies regarding effect and/or securityDKK 372,689Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid application regarding effect and/or securityDKK 372,689Generics for animals, antibioticsDKK 243,477Generics for animals, antibioticsDKK 244,002Generics for animals, antibioticsDKK 244,347Generics for animals, antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registration assessment beyond std. course due to complexity or of the submitted documentationDKK 250,046Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046			Bibliographical application	
clinical studies regarding effect and/ or security372,689Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid application without clinical studies regarding effect and/ or securityDKK 372,689Generics for animals, antibioticsDKK 243,477Generics for animals, antibioticsDKK 2442,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registration course due to complexity or of the submitted documentationDKK 50,046Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046				
effect and/ or securityApplication concerning biologically medicine that corresponds to already approved medicinesJKK 372,689Hybrid applicationDKK 372,689Hybrid applicationDKK 243,477regarding effect and/ or securityZ43,477Generics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 25,046				
Application concerning biologically medicine that corresponds to already approved medicinesDKK 372,689Hybrid applicationDKK without clinical studies regarding effect and/or securityDKK 243,477Generics for animals, antibioticsDKK 244,002Generics for animals, antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046				372,689
biologically medicine that corresponds to already approved medicines Hybrid application without clinical studies regarding effect and/or security Generics for animals, antibiotics Generic for humans DKK 242,602 Generics for animals, not antibiotics DKK 241,347 Generics for animals, not antibiotics DKK 241,347 Duplicate with same schedule as an application, where payment is made full fee Parallel registration DKK 75,633 Where payment is made full fee Dation Addition to required assessment beyond std. course due to complexity or of the submitted documentation Later expansion of DKK				DUU
corresponds to already approved medicinesHybrid application without clinical studies regarding effect and/or securityGenerics for animals, antibioticsDKK 243,477Generics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK				
approved medicinesHybrid application without clinical studies regarding effect and/ or securityDKK 243,477Generics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Parallel registrationDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046				372,689
Hybrid application without clinical studies regarding effect and/ or securityDKK 243,477Generics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Generics for animals, not antibioticsDKK 241,347Parallel registrationDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046				
without clinical studies regarding effect and/ or security Generics for animals, antibiotics DKK 242,602 Generic for humans DKK 241,347 Generics for animals, not antibiotics DUPlicate with same schedule as an application, where payment is made full fee Parallel registration DKK 74,103 Addition to required assessment beyond std. course due to complexity or of the submitted documentation Later expansion of DKK				DVV
regarding effect and/ or security Generics for animals, antibiotics DKK 242,602 Generic for humans DKK 241,347 Generics for animals, not antibiotics 241,347 Duplicate with same schedule as an application, where payment is made full fee Parallel registration DKK 74,103 Addition to required assessment beyond std. course due to complexity or of the submitted documentation Later expansion of DKK				
securityGenerics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046Later expansion ofDKK				243,477
Generics for animals, antibioticsDKK 242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 70,046Later expansion ofDKK				
antibiotics242,602Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046Later expansion ofDKK				DKK
Generic for humansDKK 241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046Later expansion ofDKK				
241,347Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046Later expansion ofDKK				
Generics for animals, not antibioticsDKK 241,347Duplicate with same schedule as an application, where payment is made full feeDKK 75,633Parallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentationDKK 50,046Later expansion ofDKK			denerie for numans	
antibiotics241,347Duplicate with sameDKKschedule as an application, where payment is made full fee75,633Parallel registrationDKK74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentation50,046VKK				211,017
antibiotics241,347Duplicate with sameDKKschedule as an application, where payment is made full fee75,633Parallel registrationDKK74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentation50,046VKK			Generics for animals, not	DKK
Duplicate with sameDKKschedule as an application, where payment is made full fee75,633Parallel registrationDKKParallel registrationDKK74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentation50,046Later expansion ofDKK				
schedule as an application, where payment is made full fee Parallel registration Addition to required assessment beyond std. course due to complexity or of the submitted documentation Later expansion of DKK				
where payment is made full feewhere payment is made full feeParallel registrationDKK 74,103Addition to requiredDKK assessment beyond std.So,046 course due to complexity or of the submitted documentationLater expansion ofDKK				
full feeParallel registrationDKK 74,103Addition to required assessment beyond std. course due to complexity or of the submitted documentation50,046Later expansion ofDKK				,
Addition to required74,103Addition to requiredDKKassessment beyond std.50,046course due to complexityor of the submitteddocumentationIter expansion of				
Addition to required74,103Addition to requiredDKKassessment beyond std.50,046course due to complexityor of the submitteddocumentationIter expansion of			Parallel registration	DKK
Addition to requiredDKKassessment beyond std.50,046course due to complexityor of the submitteddocumentationLater expansion ofDKK				74,103
assessment beyond std. 50,046 course due to complexity or of the submitted documentation Later expansion of DKK			Addition to required	
or of the submitted documentation Later expansion of DKK			-	50,046
or of the submitted documentation Later expansion of DKK				
Later expansion of DKK				
			documentation	
marketing permission 207,538			Later expansion of	DKK
			marketing permission	207,538

	Procedure	Evaluation of nariadia the	DKK
	Denmark's	Evaluation of periodic the security update gs report	8,007
	role	(PSUR) a fee per D.sp.no.	0,007
	DCP/MRP,	(1 bolt) a lee per D.sp.no.	
	RMS		
	Procedure	All applications about new	DKK
	Denmark's	marketing permission	33,766
	role		
	DCP/MRP,		
	CMS		DUU
		Addition to required	DKK
		assessment beyond standard course due to	4,691
		complexity or of the	
		submitted documentation	
		Later expansion of	DKK
		marketing permission	20,184
New market	Nature-		
driving	medicines,		
license,	traditional		
registration	plant		
and	modicinocon		
and	medicines or		
and expansion	homeopathic		
	homeopathic		DKK
	homeopathic medicines		DKK 116,789
	homeopathic medicines Procedure	-	
	homeopathic medicines Procedure Denmark's	-	116,789 DKK
	homeopathic medicines Procedure Denmark's role- National DCP,RMS	-	116,789 DKK 110,425
	homeopathic medicines	-	116,789 DKK 110,425 DKK
	homeopathic medicines		116,789 DKK 110,425 DKK 32,501
	homeopathic medicines Procedure Denmark's role- National DCP,RMS DCP/MRP, CMS All	- - - Assessment of periodic	116,789 DKK 110,425 DKK 32,501 DKK
	homeopathic medicines	security update report	116,789 DKK 110,425 DKK 32,501
	homeopathic medicines	security update report (PSUR). A fee per D.sp. no.	116,789 DKK 110,425 DKK 32,501 DKK 8,007
	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK
	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required assessment beyond std.	116,789 DKK 110,425 DKK 32,501 DKK 8,007
	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK
	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required assessment beyond std. course due to complexity	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK
expansion	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required assessment beyond std. course due to complexity or of the submitted documentation Rejection of new	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK 42,648 DKK
expansion	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required assessment beyond std. course due to complexity or of the submitted documentation Rejection of new application for marketing	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK 42,648
expansion	homeopathic medicines	security update report (PSUR). A fee per D.sp. no. Addition to required assessment beyond std. course due to complexity or of the submitted documentation Rejection of new	116,789 DKK 110,425 DKK 32,501 DKK 8,007 DKK 42,648 DKK

			1
registration	everyone		
and expansion	roles	Dest error est e e contrar	DUU
New	All types	Per export country	DKK
marketing	11 . 1		9,907
authorisation	parallel		
	import and		
	parallel trade		
New Mutual	All types	Full procedure, incl.	DKK
recognition		update	141,212
procedure,	MRP, RMS	Full procedure, incl.	DKK
MRP		administrative update	54,858
		Day Zero-procedure	DKK
			15,025
Extension of	Ordinary		
marketing	medicines		
permission/	and vitamin/		
registration	mineral-		
	preparations		
	National	1	DKK
	National		5,906
	MRP, CMS	-	DKK
			1,512
	MRP, RMS	-	DKK
	MINE, NMO		9,656
	All types		9,030
	Parallel	A fee per D.sp.no.	DKK
	import	nice per Dispino.	2,335
	Natural		2,000
	medicines,		
	traditional		
	plant		
	medicines		
	and		
	homeopathic		
	medicines		DUU
	National		DKK 9,491
Annual fee for medicines (general	All types	A fee per MT number/ drug ID	DKK 18,770
authority assignments, monitoring, control and analysis)	All Procedure		

	—	hen a medicine is manufact	ured at a compar	ny
	outside the EU			_
	Surcharge	Description		Fee
	Addition to	Addition to the fee for a		DKK
	fee for	marketing authorization if		891
	application for	manufactured outside the		
	marketing authorisation	and the Danish Medicin		
	autionisation	according to EU rules, mu company.		
_	Addition to	Supplement to the fee for a	n application to	DKK
	fee for	change the marketing auth	orization if the	891
	application to	manufacturing site for the		
	change	product is changed to a co	1 5	
	marketing	the EU/EEA area, and the D		
	authorisation	Agency, according to EU rul		
		the company		
	Supplement to	Supplement to the annual ta		DKK
	the annual fee	products manufactured		1,082
	for medicinal	EU/EEA area, if the Danish Medicines		
	products	Agency has to control the company in accordance with EU regulations.		
			egulations.	
Fee for Clinical	Fees relating	to mono-national clinical	Amoun	t
Trials		trials		
		lication for approval of a	DKK 25,5	57
		al with a medicinal product		
		a marketing authorization		
		ssued in an EU or ICH		
		onal Council for		
		ation of Technical		
	_	ents for Pharmaceuticals for		
	Human Use B For an app	lication for approval of a	DKK 50,7	4.0
		al, where documentation is	DIXK 30,7	40
		for the manufacture and		
		he investigational		
	quality of t	he investigational product in the form of an		
	quality of t medicinal	product in the form of an		
	quality of t medicinal	product in the form of an onal Medicinal Product		
	quality of t medicinal j Investigati Dossier (IN	product in the form of an onal Medicinal Product APD):		
	quality of t medicinal j Investigati Dossier (IN If the follow	product in the form of an onal Medicinal Product APD): wing is met, however, the		
	quality of t medicinal j Investigati Dossier (IN If the follow fee is the sa	product in the form of an onal Medicinal Product APD): wing is met, however, the ame as for marketed		
	quality of t medicinal j Investigati Dossier (IM If the follow fee is the sa medicinal j	product in the form of an onal Medicinal Product APD): wing is met, however, the ame as for marketed products (A):		
	quality of t medicinal j Investigati Dossier (IM If the follow fee is the sa medicinal j - The sa	product in the form of an onal Medicinal Product APD): wing is met, however, the ame as for marketed		

	API inspection outside the EU			DKK 151,181	DKK 151,181
Other Information:- Audit Fee	Corporation	Explai	nation	Application fee	Annual Fee
	Parallel imp applicatio		60 days	24 weeks (c periods for country) and p days for ap	• export bossibly 30
	National variation ty	ation 7pe II	150 days	2 mon	
	National varia	ation	60 days	2 months	
	(complete/ge and line exten National varia application ty	sions) ation	30 days	-	
TimeLine	New nation application	-	assessment time 240 days	applicant 6-12 months	
Registration			Maximum	Check stop p	eriods for
	ImagemedimedimarkbeenonlyprodeshapeCApplicatioclinical triwhich thehas approvapplicatioDAnnual feeuntil natio	 product is a modification of a medicinal product for which a marketing authorization has been issued, the modification only concerns the medicinal product's packaging, labelling, shape or appearance. Application for amendment of a clinical trial (substantial amendment), which the Danish Medicines Agency has approved. Fee for each application: Annual fee for clinical trials: The annual fee is paid per year started and until national completion, but not the first year after the approval of the trial. 			292 ,263

Guidelines	EU Guid	eline	
			Hourly price: DKK 1,267
	GMP or GLP declaration		
	Inspection of the manufacture of products or data for which import authorities require a	Inspection of a company in Denmark, where the company is not covered by a license or registration	Calculated individually based on the Danish Medicines Agency's time consumption (per started

Country		Bah	rain		
Regulatory Body	Nation	al Health Regula	atory Authority	(NHRA)	
Email ID			<u>hra.bh</u>		
Website	www.nhra.bh				
Registration Document		eCTD l	Format		
Approx. Fee	New Produc	t Registration	BD.5/-	- 5 yrs	
	& Re-registr	ation		2	
(Medical Device)	Item Type		Fees (Dinar	Norm	
			Bahraini)		
	Request to s	ubmit a	5	Each New	
	registration	request		device	
		First	150	Annual per	
	Low risk	registration		license	
		Registration	100	Annual per	
		renewal		license	
		First	300	Annual per	
	Medium	registration		license	
	Risk	Registration	200	Annual per	
		renewal		license	
		First	1,000	Annual per	
		registration		license	
		Registration	700	Annual per	
		renewal		license	
	Update m	edical device	20	Each device	
	registra	ation data			
BA BE Study Requirements	300-400 Bal				
Registration TimeLine		45 work	ting days		
Other Information:-					
Audit Fee			vices		
	Application		BHD 100	-	
		ial inspection, a	ccording to the	type of	
	facility:				
		s, pharmacies	BHD 100-200	per	
	and scientifi		inspection		
		acturers and	BHD 200-300	per	
Cuidalizas	medical dev		inspection		
Guidelines	CTD Guideli	ne			

Country			Pola	nd		
Regulatory	Office for Reg	sistration of n	nedical pro	ducts, Medical	Device and Bi	ocidal
Body	Products					
Email ID			<u>urpl@urp</u>	l.gov.pl		
Website		<u>www.urpl.gov.in</u>				
Registration		CTD Dossier				
Document						
Approx. Fee	Application for a	marketing A	uthorizati			
			63.6 0		5 – MRP, DCP	D C D
	Application	Procedure	CMS –	MRP		DCP
	for marketing	national	MRP,			(150%)
	Authorization		DCP	Preparation	Update	
			(100%)	report	report	
				evaluator	evaluator	
	full application	84,000	84,000	(75%) 63,000	(50%) 42,000	126,000
	full application: - original	84,000	84,000	63,000	42,000	120,000
	medicinal					
	product					
	- mixtures of					
	known active					
	substances in a					
	composition					
	not previously					
	used					
	substances	67,200	67,200	50,400	33,600	100,800
	with well-					
	established					
	medical use	0.7.000	05.000			40.050
	equivalent of	27,300	27,300	20,475	13,650	40,950
	the original					
	medicinal					
	product ("generic"					
	application)					
	- biological	43,680	43,680	32,760	21,840	65,520
	equivalent of	10,000	10,000	02,700	21,010	00,020
	the reference					
	product					
	- the medicinal					
	product					
	referred to in					

		1			
Art. 15					
section 12					
("hybrid" application)					
- informed					
consent					
herbal	30,576	30,576	32,760	21,840	45,864
medicinal		/	- ,	,	- ,
products other					
than those					
referred to in					
Article 20a of					
the Act					
herbal	3,024	3,024	7,560	5,040	4,536
medicinal					
products other than those					
referred to in					
Article 20a of					
the Act for					
which it was					
developed					
community					
monograph					
traditional	10,080	10,080	7,560	5,040	15,120
herbal					
medicinal					
products	27.200				
homeopathic medicinal	27,300		Notann	licabla	
products other			Not app	licable	
than those					
referred to in					
Article 21 of					
the Act					
Homeopathic					
medicinal					
products					
referred to in					
Art. 21 of the					
Act:					
- for a list					
containing less than 50					
products					
- for a list					
containing 50					
		1			

	to 100 products - for a list containing more than 100 products			
Annual Fee	Annual Fee	Procedure national	CMS	RMS
	Herbal medicinal products referred to in Art. 10 and in Art. 16 section 1 of the Act, other than those referred to in Art. 20a of the Act, or homeopathic medicinal products referred to in Art. 10 and in Art. 16 section 1 of the Act, other than those referred to in Art. 21 of the Act	2,100	2,100	2,730
	Traditional herbal medicinal products referred to in Art. 20a of the Act, and herbal medicinal products other than those referred to in Art. 20a of the Act, for which a Community monograph has been prepared	840	840	1,092
	Herbal medicinal products other than those referred to in Article 10, art. 16 section 1, art. 20 ai art. 21 of the Act Homeopathic medicinal products	840	840	1,092
	referred to in Art. 21 of the Act - for a list containing less than 50 products - for a list containing 50 to 100	621.60 1226.40	621.60 1226.40	808 1594.40
	products - for a list containing more than 100 products	1898.40	1898.40	2468

GCP Fees	 Scenario 1: GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol A at Site A (investigator site) for one clinical trial activity (Activity Group I) and at site B (sponsor site) for two clinical trial activities (Activity Group III and Activity Group IV). GCP inspection of clinical trial protocol B conducted at site C (Central laboratory) for one activity group (Activity group II); Fee payable: 4 basic fees, i.e. 22 400 EURO + 22 400 EURO + 22 400 EURO + 22 400 EURO + 22 400 EURO = 89 600 EURO; Scenario 2: GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol B at Site C (i.e. CRO site including clinical and bioanalytical facility) for two clinical trial activities (Activity Group I) and (Activity Group II). Fee payable: 2 basic fees, i.e. 22 400 EURO + 22 400 EURO = 44 800 EURO 		
Registration TimeLine		180 working days	
Other Information:-			
Audit Fee	Basic Fee (Level I)	For each inspection inside or outside the European Union; for inspections outside the European Union, travel expenses shall be charged extra on the basis of actual cost.	22 400 EURO
	Basic fee (Level II)	For each consecutive distinct plasma master file (PMF) inspection performed in conjunction with an inspection that attracts the level I fee, provided that such consecutive inspection concerns the same PMF application, the same inspection team and is conducted in the same PMF inspection tour.	11 200 EURO
	Basic fee (Level III)	For each inspection inside or outside the European Union cancelled due to the withdrawal of the application; or changes to the manufacturing arrangements made by the manufacturer or changes made by the applicant/MAH that necessitate a cancellation of the inspection before the inspection is carried out.	11 200 EURO
Guidelines	EMA Guideli		

Country	Roma	inia	
Regulatory Body	National Agency for M	edicir	nes and Medical
	Devices for		
Email ID	mdevice@	anm	l.ro
Website	www.ai		
Registration Document	Product		
Approx. Fee	Medical Products (Incl		
	The administrative	aung	EUR 5,000
	fees for the	(F	Paid when the
	marketing	(I	marketing
	authorization of a	а	uthorization
	medicinal product	u	dossier is
	under the national	SI	ibmitted with
	procedure	50	NAMMD)
	due for the		EUR 9,500
	evaluation of the		101(),000
	marketing		
	authorization dossier		
	The fees are		EUR 5,700
	generally lower for		101(5,7 00
	the evaluation of		
	generic medicines		
	for biosimilars		EUR 6,650
Medical Device	There is no administra	tive f	
Method Device	registration of medical		
	in the National Databas		-
	Devices.		
BA BE study Requirements	As per European Guide	eline f	for
	Bioavailability and Bio		
Registration TimeLine	120 D	ays	
		<u> </u>	
Other Information:-			
Audit Fee	1. Stand-alone applicat	ion	20000-30000
	(based on original da	ata)	Romanian Leu
	2.Bibliographic		20000-30000
	application (well-		Romanian Leu
	established medicina	al	
	use supported by		
	bibliographic literature)		
	3.Fixed combination		18000 -
	application (new		20000
	medicinal product m	nade	Romanian Leu
	of at least two active	!	

	substances not	
	previously authorised	
	as a fixed combination	
	medicinal product)	
	4.Generic application	22000-25000
		Romanian Leu
	5.Hybrid Application	22000-25000
	billybild lipplication	Romanian Leu
	6.Similar biological	22000-25000
	medicinal product	Romanian Leu
	7.Stand-alone application	20000-30000
	(based on original data)	Romanian Leu
	8.Bibliographic	20000-30000
	application (well-	Romanian Leu
	established medicinal	Romanian Leu
	use supported by	
	bibliographic literature)	
	9.Fixed combination	18000 -
	application (new	20000
	medicinal product made	Romanian Leu
	of at least two active	Romanian Leu
	substances not	
	previously authorised	
	as a fixed combination	
	medicinal product)	
	10. Generic	22000-25000
	application	Romanian Leu
	11. Hybrid Application	22000-25000
		Romanian Leu
	12. Similar biological	22000-25000
	medicinal product	Romanian Leu
		Romanan Deu
Guidelines	EMA Guideline	1

Country	Finland			
Regulatory Body	Finnish Medicines Agency (Fimea)			(Fimea)
Email ID	registry@fimea.fi			
Website	https://fimea.fi			
Registration Document	eCTD or NeeS			
Approx. Fee	Fees for m			isations
Approx.ree	Fee type	Hum		Veterinary
	rectype	medic	-	medicines
	Marketing –	Froi		From
	authorisation	€345,		€173,00
	application	0010,	000	0175,00
	(single strength,			
	one			
	pharmaceutical			
	form, one			
	presentation			
	Extension of	€103,	800	_
	marketing	2103,000		
	authorisation			
	(level I)			
	Type-II	€103,800		-
	variation (major			
	variation)			
	Variations	-		From €8,600
	requiring			
	assessment			
	Scientific advice	From		From
		€51,80	00 to	€17,000 to
		€103,	800	51,800
	Annual fee (level			€41,500
	I)	€123,	900	
	Establishment of	-		€86,000
	MRLs			
BA BE Study Requirements		-		
Registration TimeLine		ocessing		
	The processing times for marketing			
	authorisation applications are as follows:			as follows:
	National Proced	ure	210 d	ays
	Mutual recogniti	ion	90 da	ys + 30 days
	0		e review of	
	translations		ations	

	Decentralised procedure	210 says + 30 days for the review of translations
	Centralised Procedure	210 days + the time required by the decision process of the European Commission.
Other Information:-		
Audit Fee	-	
Guidelines	EMA guideline/ European Commission Guideline	

Country	Butan	
Regulatory Body	Drug Regulatory Authority	
Email ID	registration@dra.gov.bt	
Website	https://dra.gov.bt	
Registration Document	ASEAN Common Technical Dossier	
Approx. Fee	An initial application fee of BTN 500/- per	
**	product is levied. Once the assessment of	
	the document is completed, a registration	
	fee of BTN 1500/- per product will be	
	charged. The fees may be however revised	
	from time to time.	
	Authorisation for Sale, and export	
	1. Application fee for technical	
	authorization for sale- Nu. 900.00	
	(Nine hundred)	
	2. Late renewal of Technical	
	Authorization for sale and	
	distribution per day- Nu. 100.00 per	
	day (One hundred) per day	
	3. Application fee for renewal of	
	technical authorization for sale- Nu.	
	900.00 (Nine hundred)	
	The characterization from	
	Technical Authorization for Manufacture	
	1. Application fee for provisional	
	manufacturing authorization per	
	application – Nu. 5000.00 (five	
	thousand)	
	2. Application fee for final approval for	
	manufacturing- Nu. 5000 (Five	
	Thousand)	
	3. Fee for renewal of approval for	
	manufacturing- Nu. 500.00(Five	
	hundred)	
Renewal of Registration	Application for renewal shall be submitted	
_	within 90 calendar days before the expiry	
	date of registration along with the	
	processing fee	
BA BE Study Requirements	-	

Registration TimeLine	If all the required documents are submitted during the time of application, a medicinal product can be registered within 2-3 months.	
Other Information:-		
Inspection of Clinical Trial	 The Authority will conduct on-site inspections of the clinical trials to verify compliance to CTA. Member of the EC may be invited during the inspections as and when required. 	
Guidelines	Country Specific Guideline	

Country	Europe			
Regulatory Body	European Medicines Agency			ncy
Email ID	noncompliancre@ema.europa.u			
Website	www.ema.europa.eu			
Registration Document	Dossier			
Approx. Fee	Fees for Mark	keting A	uthorisations	5
	Fee Type		Human	Veterinary
			Medicines	Medicines
	Marketing –		From	From €173,00
	authorisation		€345,800	
	application (sing	gle		
	strength, one	C		
	pharmaceutical			
	one presentation	nj	6102.000	
	Extension of		€103,800	-
	marketing authorisation (le			
	Type-II validatio		€103,800	
	(major validation)		2103,000	-
	Scientific advice		From	€17,000 to
			€51,800 to	€51,800
	Annual fee (level I)		€103,800	
			€123,900	€41,500
	Scenario 1: Full dossier application for a medicinal product having one pharmaceutical form with one			
	strength and X p			
	Basic Fee		00 Euro	
				naceutical form
	ا معنانه م		ne presentation	1
	Additional Fee	7 400		ontations
	гее	- For additional presentations associated with the single strength.		
	Scenario 2: Full			
	product having t		• •	
	strengths and X presentations/ strength associated with the first form and one strength and Y			
	presentations associated with the second form			
	Basic Fee296 500 EURO			
	- Includes one pharmaceutical form			
	and one associated strength and one			rength and one
	presentation.			
	Additional	+7 400	EURO	
	fee			

	For additional presentations	
	associated with the first form and	
		strength.
	Additional	+29 800 EURO
	fee	Second strength associated with the
		first form including one presentation.
	Additional	+7 400 EURO
	Fee	For additional presentations
		associated with the first form and
		second strength.
-	Additional	+29 800 EURO
	fee	Second form including its associated
		strength and one presentation.
-	Additional	+ 7 400 EURO
	fee	For additional presentations
		associated with the second form and
		its strength.
	Scenario 3: Fu	ll dossier application for an insulin
	product having	two pharmaceutical forms with six
	strengths (cons	isting of two sets of one uncombined
	preparation and	l two combination preparations
	(having differen	t proportions of insulin) with insulin
	amounts corres	ponding to A I.U. and B I.U.) and X
	presentations/strength associated with the first form and two strengths (of un-combined preparations with	
	insulin amounts	s corresponding to A I.U. and B I.U.)
	and Y presentat	ions/strength associated with the
	second form	
	Basic Fee	296 500 EURO
		- Includes one pharmaceutical form
		and one associated strength and one
		presentation.
	Additional	+ 7 400 EURO
	Fee	 For additional presentations
		associated with the first form and
		strength.
	Additional	+ 29 800 EURO
	fee	 For second to sixth strengths
		associated with the first form
		including one presentation for each
		strength.
	Additional	+ 7 400 EURO
	fee	 Additional presentations
		associated with the second to sixth
		strengths of the first form.

	Additional	+ 29 800 EURO	
	fee	Second form including one	
		associated strength and one	
		presentation.	
	Additional	+ 7 400 EURO	
	fee	For additional presentations	
		associated with the second form and	
		first strength.	
	Additional	+ 29 800 EURO	
	fee	-Second strength associated with the	
		second form including one	
		presentation.	
	Additional	+ 7 400 EURO	
	fee	For additional presentations	
		associated with the second form and	
		second strength.	
	Scenario 4: Fu	ll dossier application with 3 strengths,	
		mg and 300mg. The 100 and 200mg	
	strengths will b	e packaged together in a starter pack	
	and the 300mg	strength will have two presentations.	
	-	Omg strengths do not have additional	
	presentations.		
	Basic Fee	296 500 EURO	
		Includes one pharmaceutical form	
		and one associated strength and the	
		starter pack presentation.	
	Additional	+ 29 800 EURO	
	Fee	For second and third strengths	
		associated with the first form	
		including presentation 1 for the 3rd	
		strength.	
	Additional	+7 400	
	Fee	Additional presentation 2 associated	
	100	with the third strength of the first	
		form.	
	Examples of th	e determination of fees for	
		narketing authorisation	
		w pharmaceutical form with two	
		presentations/strength, for	
	authorised or new route of administration (with submitted/cross-referenced clinical data)		
	Extension Application:		
	One pharmaceutical form, first strength and X presentations		
	presentations Second strongth (of same new pharmaceutical		
	 Second strength (of same new pharmaceutical form) and V procentations 		
	form) and X presentations		

	Basic Fee	89 900 EURO	
	Dasit ree	For extension	
-	Additional		
	Additional	+ 7 400 EURO	
	fee	For additional presentation fees.	
	Additional	+ 22 400 EURO	
	fee	For additional strength fee.	
	Additional	+ 7 400 EURO	
-	Fee	For additional strength fee	
		w route of administration for	
	-	maceutical form with two authorised	
	-	presentations/strength (with	
		s-referenced clinical data)	
	Extension app	lication:	
		administration for authorised	
	pharmac	eutical form, first strength and X	
	presenta	tions	
		trength (same new route of	
		ration for same authorised	
	A	eutical form) and X presentations	
	Basic Fee	89 000 EURO	
		For Extension	
	Additional	+ 7 400 EURO	
	Fee	For additional presentation fees.	
	Additional	+ 22 400 EURO	
	Fee	For additional strength fee.	
	Additional	+ 7 400 EURO	
	Fee	For additional presentation fees.	
	Scenario 3: Tw	o new strengths of same authorised	
	pharmaceutical	form and X presentations/strength	
	(without submit	tted/cross-referenced clinical data)	
	Extension App	lication :	
	 First nev 	v strength and X presentations	
	 Second n 	new strength (of same authorised	
	pharmac	eutical form) and X presentations	
	Basic Fee	66 800 EURO	
		For extension	
	Additional	+ 7 400 EURO	
	FeeFor additional presentation feesAdditional+ 22 400 EUROFeeFor additional strength fee.Additional+ 7 400 EUROFeeFor additional presentation fees.Scenario 4:		
	One new strength of each of two authorised		
	pharmaceutical forms and X presentations/strength		
	(without submitted/cross-referenced clinical data)		

	 amounts corresponding to A I.U. and B I.U.) and X presentations/ strength associated with the first form; and two strengths (of un-combined preparations with insulin amounts corresponding to A I.U. and B I.U.) and Y presentations/strength associated with the second form Strengths associated with a pharmaceutical form: Six strengths associated with first pharmaceutical form Two strengths associated with second pharmaceutical form 		
	Basic Fee	14 600 EURO For renewal	
	Additional Fee	+ 14 600 EURO For renewal	
BA BE Study	As per EMEA Guideline		
Requirements			
Devictory T ¹	D J	D	
Registration TimeLine	Procedure Centralized Procedure	Days	
		210 Days	
	Decentralised Procedure	120 Days	
	National Procedure	210 Days	
	Mutual Recognition Procedure	90 Days	
	Procedure		
Other Information:-			
Audit Fee	Examples of the determination of fees for GMP		
	inspections		
	Scenario 1: GMP inspectio	n of manufacturing site 1	
	for one medicinal product		
	pharmaceutical forms: cap	sules (non-sterile) and	
	solution for injection (steri	le). The manufacturing	
		aceutical forms is the same,	
	i.e. manufacture of the finis	shed product.	
	Fee payable: 2 basic fees (level I), i.e. 22 400 EURO + 22 400 EURO = 44 800 EURO Rationale: there are two types of dosages forms (sterile and non-sterile) and each one attracts a basic fee (Level I).		
	Scenario 2: GMP inspection of manufacturing site 1 for two medicinal products (A and B). Product A involves only one pharmaceutical form (capsules) and one pharmaceutical activity (primary packaging). Product B also involves one pharmaceutical form		

	 (tablets) and four manufacturing activities (manufacture of the active substance, quality control of the active substance, manufacture of the finished product and primary packaging). Fee payable: 3 basic fees (Level I), i.e. 22 400 EURO + 22 400 EURO + 22 400 EURO = 67 200 EURO
	Examples of the determination of fees for GCP inspections
	Scenario 1: GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol A at Site A (investigator site) for one clinical trial activity (Activity Group I) and at site B (sponsor site) for two clinical trial activities (Activity Group III and Activity Group IV). GCP inspection of clinical trial protocol B conducted at site C (Central laboratory) for one activity group (Activity group II);
	Fee payable: 4 basic fees, i.e. 22 400 EURO + 22 400 EURO + 22 400 EURO + 22 400 EURO = 89 600 EURO;
	Scenario 2: GCP inspection request for Product A marketing authorisation application and the conduct of clinical trial protocol B at Site C (i.e. CRO site including clinical and bioanalytical facility) for two clinical trial activities (Activity Group I) and (Activity Group II).
	Fee payable: 2 basic fees, i.e. 22 400 EURO + 22 400 EURO = 44 800 EURO
Guidelines	EMA Guideline

Country	Croatia		
Regulatory Body	Agency for Medical Products and Medical Devices of		
Regulatory Douy	Croatia		
	HALMED- Agencija za lijekove I medicinske		
	proizvode		
Email ID	pisarnica@ha		
Website	www.halm		
	Medical Product D		
Registration Document	National Procedures		
Approx. Fee		20,000,00,000	
	1. For one strength and	30.000,00 HRK	
	pharmaceutical form	24 000 00 UDV	
	2. For an additional	24.000,00 HRK	
	pharmaceutical form		
	3. Issuing of Plasma Master	20.000,00 HRK	
	File certificate		
	MRP/DCP Procedures		
	When Croatia acts as a Refe	erence Member states	
	(RMS)		
	1. For one strength and	200.000,00 HRK	
	pharmaceutical form		
	2. For one strength and	150.000,00 HRK	
	pharmaceutical form		
	3. For one strength and	185.000,00 HRK	
	pharmaceutical form -		
	medicinal product with		
	well-established		
	medicinal use		
	4. For one strength and	185.000,00 HRK	
	pharmaceutical form -		
	hybrid, biosimilar		
	medicinal product		
	5. For one strength and	75.000,00 HRK	
	pharmaceutical form -		
	with the consent to use		
	the dossier of a		
	reference medicinal		
	product		
	6. For one strength and	185.000,00 HRK	
	pharmaceutical form -		
	new combination of		
	known active		
	substances	400.000.00.00	
	7. For an additional	100.000,00 HRK	
	pharmaceutical form (at		
	the same time)		

8. For an additional	120 000 00 1101/
	120.000,00 HRK
pharmaceutical form	
(subsequently) 9. For an additional	75.000,00 HRK
	7 3.000,00 NKK
strength (at the same	
time) 10. For an additional	
	85.000,00 HRK
strength (subsequently)	where Chate (CMC)
Croatia is a Concerned Me	
1. For one strength and	30.000,00 HRK
pharmaceutical form	
2. For one strength and	30.000,00 HRK
pharmaceutical form -	
generic medicinal product	
3. For one strength and	30.000,00 HRK
pharmaceutical form -	
hybrid, biosimilar	
medicinal product	
4. For one strength and	30.000,00 HRK
pharmaceutical form -	
with the consent to use	
the dossier of a reference	
medicinal product	
5. For one strength and	30.000,00 HRK
pharmaceutical form -	
new combination of	
known active substances	
6. For an additional	24.000,00 HRK
pharmaceutical form	
(submitted at the same	
time)	
7. For an additional	30.000,00 HRK
pharmaceutical form	
(submitted subsequently)	
8. For an additional	14.000,00 HRK
strength (submitted at the	
same time)	
9. For an additional	16.000,00 HRK
strength (submitted	
subsequently)	
Repeat use procedure	
1. For one strength and	30.000,00 HRK
pharmaceutical form	
2. For an additional	24.000,00 HRK
pharmaceutical form	
(submitted at the same time)	

3. For an additional	30.000,00 HRK
pharmaceutical form	
(submitted subsequently)	
4. For an additional	14.000,00 HRK
	14.000,00 11111
strength (submitted at the	
same time)	4 6 000 00 1151
5. For an additional	16.000,00 HRK
strength (submitted	
subsequently)	
Registration/refusal of refusal of	stration of a traditional
herbal medicinal product	
In a national procedure	
For one strength and	11.000,00 HRK
pharmaceutical form -	11.000,00 11111
traditional herbal	
medicinal product (based	
on an EU monograph)	10,000,00,00
For one strength and	18.000,00 HRK
pharmaceutical form -	
(when there is no EU	
monograph)	
For an additional	9.000,00 HRK
pharmaceutical form of a	
traditional herbal	
medicinal product	
(submitted at the same	
time)	
	11 000 00 UDV
For an additional	11.000,00 HRK
pharmaceutical form	
based on an EU	
monograph (submitted	
subsequently)	
For an additional	18.000,00 HRK
pharmaceutical form	
when there is no EU	
monograph (submitted	
subsequently)	
For an additional strength	7.000,00 HRK
of a traditional herbal	7.000,00 11111
medicinal product	
(submitted at the same	
time)	
For an additional strength	8.000,00 HRK
of a traditional herbal	
medicinal product	
(submitted subsequently)	
(submitted subsequently)	l

In a Mutual Recognition or I	Decentralization	
In a Mutual Recognition or Decentralization Procedure when Croatia acts as a Reference Member		
State (RMS)		
For one strength and	40.000,00 HRK	
pharmaceutical form -		
traditional herbal		
medicinal product		
For an additional	32.000,00 HRK	
pharmaceutical form of a		
traditional herbal		
medicinal product		
(submitted at the same		
 time)		
For an additional	40.000,00 HRK	
pharmaceutical form of a		
traditional herbal		
medicinal product		
(submitted subsequently)	40.000.00.00	
For an additional strength	19.000,00 HRK	
of a traditional herbal		
medicinal product (submitted at the same		
time)		
For an additional strength	21.000,00 HRK	
of a traditional herbal	21.000,00 mm	
medicinal product		
(submitted subsequently)		
In a Mutual Recognition of	r Decentralization	
Procedure when Croatia is		
State		
For one strength and	18.000,00 HRK	
pharmaceutical form -		
traditional herbal		
medicinal product		
For an additional	9.000,00 HRK	
pharmaceutical form of a		
traditional herbal		
medicinal product		
(submitted at the same		
time)		
For an additional	18.000,00 HRK	
pharmaceutical form of a		
traditional herbal		
medicinal product		
(submitted subsequently		

	For an additional strength of a traditional herbal medicinal product (submitted at the same time)	7.000,00 HRK	
	For an additional strength of a traditional herbal medicinal product (submitted subsequently)	8.000,00 HRK	
	Clinical trial of unauthoris	· · · · · · · · · · · · · · · · · · ·	
	Service	Price	
	Mono-national trial - Part I	15.000,00 HRK	
	Mono-national trial - Part II	8.000,00 HRK	
	Multinational trial - Croatia RMS - Part I	40.000,00 HRK	
	Multinational trial - Croatia RMS - Part II	8.000,00 HRK	
	Non-commercial clinical trials	Free of Charge	
	Clinical trial of authorized medicinal product		
	Mono-national trial - Part I	10.000,00 HRK	
	Mono-national trial - Part II	5.000,00 HRK	
	Multinational trial - Croatia RMS - Part I	35.000,00 HRK	
	Multinational trial - Croatia RMS - Part II	5.000,00 HRK	
		•	
Registration TimeLine	Centralized Procedure – 21	0 Days	
	Mutual Recognition Procedu	5	
	National Procedures- 210 D		
	Decentralized Procedure- 2	0	
Other Information:-			
Audit Fee	Manufacturing a	and Inspection	
	Service	Price	
	1. Granting/refusal of a	5.000,00 HRK	
	manufacturing licence		
	2. Variation of a	2.000,00 HRK	
	manufacturing licence		
	3. Revocation of a	2.000,00 HRK	
	manufacturing licence		
	4. Good Manufacturing Practice (GMP) certificate,	5.000,00 HRK	

for manufacturers outside	
of Croatia	
5. Good Manufacturing	1.000,00 HRK
Practice (GMP) certificate	1.000,00 111/1
6. Good Manufacturing	7.000,00 HRK
0	7.000,00 HKK
Practice inspection and	
Good Pharmacovigilance	
inspection	
Medical Product Marketin Service	g Price
 1. Approval for an import of an active substance	1.000,00 HRK
2. Approval for the	2.000,00 HRK
exemption to the labelling	
and/or package leaflet	
obligation	
Annual Fees	
Service	Price
1. Annual fee for a	4.800,00 HRK
medicinal product	
2. Annual fee for a	500,00 HRK
homeopathic medicinal	
product/device	
3. Annual fee for	300,00 HRK
registration in the register	
of custom made medical	
device manufacturers	
Medical Devices	
Service	Price
1. Registration/refusal of	5.000,00 HRK
registration in the register	
of manufacturers or	
manufacturer	
representatives	
2. Variation/refusal of	1.000,00 HRK
variation of registration in	
the register of	
	1
manufacturers or	
manufacturers or authorized manufacturer	
authorized manufacturer	6.000,00 HRK
authorized manufacturer representatives 3. Registration/refusal of	6.000,00 HRK
authorized manufacturer representatives 3. Registration/refusal of registration in the register	6.000,00 HRK
authorized manufacturer representatives 3. Registration/refusal of registration in the register of medical devices (1 to 5	6.000,00 HRK
authorized manufacturer representatives 3. Registration/refusal of registration in the register of medical devices (1 to 5 devices)	
authorized manufacturer representatives 3. Registration/refusal of registration in the register of medical devices (1 to 5	6.000,00 HRK 6.500,00 HRK

	of medical devices (6 to 30 devices)	
	5. Registration/refusal of registration in the register of medical devices for over 30 medical devices	7.000,00 HRK
Guidelines	ICH Guidelines	

Country	Cambodia				
Regulatory Body	Department of Drug, Food and Cosmetics				
Email ID		Info.campor@moh.gov.kh			
Website		W	ww.ddfca	ambodia.co	m
Registration Document	ASEAN			chnical Dossi	
Approx. Fee	Types of		Appli	cable Fee	Applicable Fee
	Authorization				in USD
	Drugs (new	r)	90	00000	USD 220
			Camb	odian riel	approx.
	Drugs (renew	val)	50)5000	USD 120
			Camb	odian riel	approx.
BA BE Study	As Per ASEAN				NDUCT OF
Requirements	BIOEQUIVALI	ENCI	E STUDIE	S	
Registration TimeLine	Application		eening	Evaluation	0 1
	submission	P	ocess	Process	Decision
	New	2	days	4 Months	2 month
	Chemical				(Decided by
	Entity				committee
					meeting
					every 2
					months
	Generic	2	days	3 Months	2 Months
	product				(committee
					meeting)
	Minor	2	days	2 weeks	2 weeks
	Variation	-		1 Marcha	2
	Major	2	days	1 Months	2 weeks
	Variation	-		(all a	
	Renewal	2	days	6 weeks	2 Months
					(Committee
					meeting)
Other Information:-					
Audit Fee	200 000 Khm	or D	oile		
Guidelines		200,000 Khmer Reils ICH CTD Guideline			
Guidelines		CHIR	-		

Country	Czech Republic		
Regulatory Body	Ministry of Health / Státní ústav pro kontrolu léčiv		
Email ID	posta	@sukl.cz	
Website		v.sukl.cz	
Registration Document		Format	
Approx. Fee	Application for Marke National Procedure	eting Authorisation,	
	Activity	Fees	
	Article 8(3)	9 600,00 €	
	application - new		
	active substance		
	Article 8(3)	8 000,00 €	
	application - known		
	active substance		
	Article 10a well	6 400,00 €	
	established use		
	application		
	Article 10(1) generic	8 000,00 €	
	application		
	Article 10(3) hybrid	8 500,00 €	
	application		
	Article 10b fixed	8 000,00 €	
	combination		
	application		
		rketing Authorisation, DCP-CMS	
	Article 8(3)	6 000,00 €	
	application - new	,	
	active substance		
	Article 8(3)	5 000,00 €	
	application - known		
	active substance		
	Article 10(1) generic	5 000,00 €	
	application		
	Article 10(3) hybrid	5 500,00 €	
	application		
	Article 10b fixed	5 000,00 €	
	combination		
	application		

BA BE Study Requirements	As per European Guideline			
Registration TimeLine	Centralized Procedure – 210 Working Days			
	Mutual Recognition Procedure- 390 Working			
	Days	0		
	National Procedures- 210 V	Working Davs		
	Decentralized Procedure- 2			
Other Information:-				
Annual Maintenance Fee	Sub-category or	Amount of cost		
	specification	reimbursement		
	Performance of expert	19,500 CZK		
	activities associated with			
	the maintenance of a			
	medicinal product			
	marketing authorisation,			
	except for cases listed			
	under codes U-002, U-			
	003, U-004, and U-005			
	Performance of expert	39,100 CZK		
	activities associated with			
	the maintenance of a			
	medicinal product			
	marketing authorisation			
	where the Czech Republic			
	is the Reference Member			
	State			
	Performance of expert	3,000 CZK		
	activities associated with			
	the maintenance of a			
	marketing authorisation			
	of a homeopathic product			
	Performance of expert	5,000 CZK		
	activities associated with			
	the maintenance of a			
	medicinal product			
	marketing authorisation			
	where the MA holder is a			
	micro-enterprise			
	Performance of expert	9,500 CZK		
	activities associated with			
	the maintenance of a			
	medicinal product			
	marketing authorisation			
	where the MA holder is a			
	small company and it			

	does not involve homeopathic products	
Guidelines	EMA,EC,CMD and HMA guidelines	

Country	Nigeria				
Regulatory Body	National Agency for Food & Drug Administration (NAFDAC)				
Email ID	nafdac@nafdac.gov.ng				
Website		www.nafdac.gov.	ng		
Registration		CTD Dossier			
Document					
Approx. Fee		Registration			
	Herbal and		Full Registration:		
	Nutraceuticals/Alte	rnative	\$1,252.00		
	Medicines (per proc	luct)	Listing: \$		
	Descrip		Local	Foreign	
	Medical De		20,000	\$ 750.00	
	Medical De	vices 2*	20,000	\$874.00	
	Over the Counter N	Aedicines (OTC)	80,000	\$ 967.00	
	Orphan		80,000	\$ 967.00	
	Prescription Only N	/ledicines (POM)	80,000	\$	
	1*			1,280.00	
	Prescription Only N	/ledicines (POM)	80,000	\$	
	2*			1,200.00	
	Vaccines/Bi	ologicals	80,000	\$	
				1,200.00	
	Veterinary Me		80,000	\$	
	Supplen	nents		1,200.00	
		egistration Rene	wal 80 % of New		
	Registration Ren				
			registra	ation Cost	
Fees for Clinical Trials	Description	Industry-	Industry-		
rees for chinear ritials	Description	Sponsored /	Sponsor		
		Locally-	Importe		
		developed IMP	Importe	u min	
	Application	250,000	\$2,747.25		
	1. Individual	NA	ΨΔ,ΓΙΓ.ΔΟ		
	2. Research	NA			
	Institution				
	3. Dossier/Clinical	NA	50,000		
	data review		,		
	4. Extension of	50,000	\$2,747.2	5	
	study				

	Inspection	350,000.00	\$5,494.51			
	Routine Inspection	350,000	\$2,747.25			
Registration TimeLine	1. Registration of fo	. ,				
	acceptance of app	_				
	2. Registration of fo	ore than 120) davs			
	from acceptance		uuje			
		3. Variation of product registration takes not m				
	days					
	Summary of Regist	tration Process w	vith Timelir	nes		
		Submission of Application				
	Document Ve		0 da 10 d	<i>y</i>		
	Facility Inspection		20 days f			
	Je J	F F O	and 10 day			
	Laboratory	Analysis	30 days fo			
		5	days fo			
	Final Ve	tting	10 c			
	Approval Meetin	-	20 d	lays		
	NAFDAC registra	ation Number		-		
	(Certificate of r	egistration)				
	Total number of day	ys: 90 days for Foo	od, 120 days	for Drugs		
Other Information:-						
Audit Fee	Pharmaceuticals: (Per Line for Loca	al; Per Site f	for		
	Foreign)					
	Description		Local	Foreign		
	Pre-Production: Sm	all Scale	50,000			
	Pre-Production: Me	dium/ Large	70,000			
	Scale			NA		
	Production: Medium	n/Large Scale	170,000			
	(Renewable yearly)					
	Veterinary Cosmetic	•	erbal Produ	cts (Per		
	Line for Local; Per S	• •	1	T		
	Production: Micro E	nterprise	15,000			
	(Renewable yearly)					
	Production: Small S	cale (Renewable	30,000	NT 4		
	yearly)		40.000	NA		
	Production: Medium	n/Large Scale	40,000			
	(Renewable yearly)					
Guidelines	ICH CTD Guideline					

Regulatory Consultancy Charges and	Regulatory	Consultancy	Charges and Fees	5
---	------------	-------------	-------------------------	---

Per Product Charges Approx. For Consultants				
Regulatory Dossier	B.A-B.E	Dossier	Registration	
eCTD		Preparations		
	USD \$ 28,849.15- USD	USD \$ 2400- USD	USD \$ 3600	
Regulated	\$ 48081.92	\$ 6000		
	USD \$ 21000- USD \$	USD \$ 960	USD \$ 1000	
Semi-Regulated	24000			
ROW (Rest of Other	USD \$ 7200- USD \$	USD \$ 500	USD \$ 500	
World)	12000			

(Excluding Expenses)								
Product	Strength	Mfg Rate	Batch Qty	Investment	Sale Rate Domestic	Sale Rate Export	Approx Profit Domestic	Export Profit
Sildenafil Tablet	100	7.5	5000	37500	9.375	11.25	9375	18750
Sildenafil Tablet	50	9.5	5000	47500	11.875	14.25	11875	23750
Tadalafil	10	10	5000	50000	12.5	15	12500	25000
Tadalafil	20	13	5000	65000	16.25	19.5	16250	32500
Sildenafil Gel	100 mg	6.75	150000	1012500	8.4375	10.125	253125	506250
Tadalafil Gel	20 mg	6	150000	900000	7.5	9	225000	450000
Protein Powder	Nutra	55	1000	55000	145	200	90000	145000
Protein Powder -plant	200 gm	165	1000	165000	999	499.5	834000	334500
Protein Powder whey	1 Kg	1650	1000	1650000	2999	1499.5	1349000	-150500
Piles Tablet	60 Tab	175	1000	175000	999	499.5	824000	324500
Vitmine Tablets	60Tab	185	1000	185000	999	499.5	814000	314500
Diabetes Tablet	60 Tab	210	1000	210000	999	499.5	789000	289500
Sex Enhancement Tablets	60Tab	210	1000	210000	999	499.5	789000	289500
				4762500			6017125	2603250

11.0 Example of Sales Profit Calculations Against Investment :

*Rates May Change from manufacturer to manufacturer

*Except for Drug Products all Nutra MRP and SALE RATE is open and not having any restrictions *Nutra Domestic SALE RATES ARE FOR customers IT MAY VARY OF SELLING TO DISTRIBUTORS

**Interpretation: In the Investment of 4762500.00 Company Can Earn around 2603250 (50%) Profit On An Average

12.0 Steps To Start: Generating Leads

<u>Sr.No.</u>	Particulars
01	Open an Office In Mumbai or Anywhere else
02	Website finalization
03	Product Portfolio Display On the Website with Photo
04	Company Boucher in Print or Digital
05	Email Ids
06	Staff Appointment
07	Email communication and Data searching By Staff for Domestic as well as Overseas
	Business
08	If Enquiry generated Sourcing of Products and Making Agreements with Manufacturers

13.0 Advertisement and Marketing

There are many ways to advertise and market pharmaceutical products:

Domestic Market:

- 1. Generic Market :
 - a. This is a direct retail or distributor market that has very Fewer margins and does not require much marketing
 - b. This is channel marketing through distributors
- 2. Ethical Marketing /Prescription Market :
 - a. If a company is willing to enter into an ethical market margins and profit ratio is more
 - b. Huge manpower and marketing expenses so require more investment
 - c. Risk of bad debts
- 3. Advertisement :
 - a. Through Marketing Representatives for Ethical market and Generic through Distributors Network

Export Market :

- 1. Searching Clients on various Portals
- 2. Searching overseas Distributors or Importers through emails LinkedIn and different portal
- 3. One to One to One Telephonic Communication with clients

Direct Customer :

- 1. Launching Products on different portals
- 2. Social Media Advertisement
- 3. Setting up a Delivery channel
- 4. MLM Marketing Concept

14.0 Manufacturer Selection

1. Pharma Manufacturing :

D AND D Pharma team shall be very careful while selecting a manufacturer :

- 1. Check what certifications manufacturers are having generally for exports basic is WHO Approval
- 2. Check the Quality background of the manufacturer
- 3. Check-in which courtiers manufacturer is supplying already, the manufacturer who is supplying most of the countries or many countries is not a good choice for doing business with such manufacturers as they already have connections and suppliers in that country which may conflict with our or their business interest
- 4. The capacity of the Manufacturer must be checked
- 5. Visit to every unit is a must

Checklist for Selection of Manufacturers:

Sr No	Particulars
01	Manufactures all Manufacturing License must be checked
02	Do these manufacturers have WHO Certification?
03	If these manufacturers have any other countries' certification
04	How many countries manufacturers are catering and how many are registered? Is there any country where registration is done but Business has not started

05	Has this manufacturer received any warning from the FDA for
	any quality failure?
06	What is factory size Small scale Middle scale or Large scale?

15.0 Other Pharma Business which can be Initiated

1. Pharma API and Intermediate Business:

Export of API and Intermediate to Pharmaceutical companies and herbal premixes for Nutraceutical Companies is also a huge business to do from India

2. Essential Oils and Perfume natural extracts:

Middle East and all Arabic countries are importing Essential Floral oils or natural essences from India which is a valuable market these oils are being used in Perfumes which have major consumption in Arabic countries

16.0 Risk Analysis :

Probable Risks while doing Pharma Business :

1. Misguidance and Miscommunication with staff :

Promotors of Business must have a close watch and must learn all the concepts of pharma business on a Micro level, dependencies on staff and employees may put the business in danger.

2. proper arrangement of Funding :

It is necessary to arrange funding for supplies, timely supplies will maintain business consistency. You can not depend on credit and loans for this business.

3. Quality of Product :

The quality of the Product is the most important part and promotors must ensure the quality of the product before launching it in the market

4. Over Qualified Materials :

If the requirement is of WHO Approved factory and if we are delivering material from EU Approved factory this does not make sense as it won't give more profit, the production cost is and in this case, a business may be in a financial crunch we can send materials which are overqualified to any non-regulated markets as there is three times rate difference for regulated material, need to identified the same with country to country distributors **15. Procedure to be Followed after receiving Enquiry :**

When D and D Pharma will receive any global enquiry first need to check with manufacturers about availability of Registration in the buyer country.

If a company is registered with the Country then ask for the dossier of the products and if the dossier is not available check the availability of documents for dossier compilation

If the company does not have documents for the product then change the manufacturer.

What Documents shall we ask to manufacturer:

- 1. Product License /FSC /GMP /COPP
- 2. WHO Certificate
- 3. Country Registration certificate
- 4. COA of Product (For sending to the client immediately to gain trust)
- 5. Dossier or Dossier registration certificate
- 6. Product samples
- 7. Rates

General Terms of Agreement :

The company CAN CHARGE Around 15000 INR To 30000 INR for the dossier and in the first consignment it can be refunded to the manufacturer

Audit charges shall be contributed as 50-50%

If the new country is there audit charges shall be put in the buyer's account.

Carefully discuss BA BE CHARGES if the manufacturer is asking for the same then it has to be on an exclusivity basis.

Sr No	Content
01	Heading Slide
02	Company Introduction
03	Vision Mission Quality Policy
04	Management
05	Project Vision: Brand Building
06	Financial
07	Product Portfolio and brand description
08	Targeted Countries: Not more than 10
09	Manufacturers Support
10.	Agreements Finalized with manufacturers
11	Advertisement Policy if a Consumer product
12	Closing Statement and Future Growth

17.0 Investor Presentation Content

18.0 Global Reports: SILDENAFIL

Global Sildenafil Market, By Product Type (Branded and Generics), Application (Peripheral Vasodilator and Erectile Dysfunction), End-Users (Clinics, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Market Analysis and Insights: Global Sildenafil Market

The sildenafil market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.80% and is expected to reach USD 2,096.19 million by 2028 in the above-mentioned research forecast period. Presence of branded drugs and increasing prevalence of erectile dysfunction worldwide.

Moreover, rising awareness and increasing prevalence of diabetes and obesity also boost the market growth. The growing geriatric population and rising healthcare expenditure act as an opportunity for market growth. However, side effects caused by drugs and a strict regulatory framework may hamper the global sildenafil market.

Sildenafil is a phosphodiesterase inhibitor and is indicated for the treatment of erectile dysfunction in men. This medicine improves the exercise ability in adults suffering from pulmonary arterial hypertension. It treats erectile dysfunction by enhancing the blood flow to the penis during sexual stimulation. This increase in blood flow leads to an erection. Sildenafil works by relaxing the blood vessels of the lungs, which allows easy blood flow.

As per the studies conducted, this has been reported that erectile dysfunction is highly prevalent with a 3-76.5% prevalence rate and it increases with an increase in age. This affected population is hugely dependent upon sildenafil to achieve better treatment, hence providing lucrative growth.

This sildenafil market provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions,



product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Sildenafil Market Scope and Market Size

The sildenafil market is segmented based on product type, application, end-users, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

- Based on product type, the sildenafil market is segmented into branded and generics.
- Based on application, the sildenafil market is segmented into peripheral vasodilator and erectile dysfunction.

- Based on end-users, the sildenafil market is segmented into clinics, hospitals, and others.
- Based on distribution channels, the sildenafil market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Sildenafil Market Country-Level Analysis

The sildenafil market is analyzed and market size information is provided by country, product type, application, end-users, and distribution channel as referenced above.

The countries covered in the sildenafil market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts for the largest market share due to branded drugs and the high acceptance of well-recognized drugs. Europe is also expected to grow exponentially due to established healthcare and research and development activities. Asia-Pacific is expected to account for the largest market share due to the rising prevalence of erectile dysfunction-causing infections, the growing geriatric population, and increasing government initiatives for the growth of pharmaceutical industries.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Sildenafil market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to the market growth is analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Sildenafil Market Share Analysis

Sildenafil market competitive landscape provides details by competitor details including are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies' focus related to the Sildenafil market.

The major players covered in the sildenafil market are Pfizer Inc., Century Pharmaceuticals Ltd., Polpharma, Deva Holdings, Actavis, Inc., Accord-UK Ltd., Mantra Pharma, ANGITA, Apotex Inc., Bayer AG, Ritz Formulations Pvt. Ltd., Cipla, Abbott, Viatris Inc., Sandoz, Hetero Healthcare Limited, Delphis Pharma, Teva Pharmaceuticals USA, Inc., Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Umang Pharmaceuticals among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

TADALAFIL MARKET

The global tadalafil market is expected to grow at a considerable CAGR during the forecast period (2022-2028). Male sexual function disorders including impotence or erectile dysfunction-ED are treated with tadalafil when used in conjunction with sexual stimulation, enabling a man to get and maintain an erection by boosting blood flow to the penis. Additionally, tadalafil is a drug that is used to treat the signs and symptoms of prostate enlargement (benign prostatic hyperplasia-BPH). It helps to relieve BPH symptoms including having problems initiating a pee stream, having a weak stream, and needing to urinate frequently or urgently (including during the middle of the night). When tadalafil is taken, the smooth muscle in the prostate and bladder is thought to relax.

Various growth methods, including partnerships and collaborations, mergers and acquisitions, geographical development, and new product releases, are significantly adopted by the leading companies in the field to stay competitive in the marketplace. For instance, in March 2020, the launch dates for Tadalafil tablets (the branded product: Cialis) were announced by Sawai Pharmaceutical Co., Ltd. The company launched tadalafil tablets 10 mg CI, and tadalafil tablets 20 mg CI in March 2020.

Additionally, the growing use of drugs such as Sildenafil (Viagra), Vardenafil (Levitra, Staxyn), and Avanafil (Stendra), among others restrain the growth of the tadalafil market. The rising prevalence of erectile dysfunction mainly in Japan is a major element driving market growth.


Impact of COVID-19 on Global Tadalafil Market.

The COVID-19 has benefited the tadalafil market. The COVID-19-infected persons were more than 5 times more likely to acquire ED (erectile dysfunction). Stress, worry, and sadness caused by COVID-19 can affect sexual health and contribute to ED. ED might be an indication of heart disease in its early stages. COVID-19 can affect heart health. This is because it might create inflammation in many places of your body. This includes the heart and, additionally, the adjacent blood capillaries and veins. These factors have increased the demand for tadalafil hence raising the growth of the tadalafil market globally.

Segmental Outlook

The global tadalafil market is segmented based on type and application. Based on type, the market is sub-segmented into Purity: 98% and Purity: above 98%. Based on application the market is sub-segmented into erectile dysfunction, benign prostatic hyperplasia, and others.

**The above-mentioned segments can be customized as per the requirements.



Global Tadalafil Market Share by Product, 2021(%)

Purity: 98% Segment is holding a Prominent Share in the Global Tadalafil Market.

Based on type, purity: 98% is anticipated to hold a prominent share in the market. Further, Maiden Pharmaceutical Ltd. has made Tadalafil (Adcirca) a phosphodiesterase (PDE) inhibitor used to treat erectile dysfunction in men. During stimulation, it increases blood flow to the penis.

Regional Outlooks

The global tadalafil market is further segmented based on geography Including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). North America is anticipated to hold a lucrative share in the market owing to the presence of market players coupled with increasing healthcare expenditure in the region.

Global Tadalafil Market Growth, by Region 2022-2028



The Asia-Pacific is expected to witness the highest growth rate in the Global Tadalafil Market.

The global tadalafil market is anticipated to be dominated by the Asia-Pacific, and this trend is expected to continue during the forecast period. Japan has the highest percentage of erectile dysfunction followed by China and US and Brazil having the lowest. According to data at the sixth Asian Congress of Sexology in Kobe, one in three Japanese men indicated they suffer from erectile dysfunction in a recent poll. With age, ED becomes more common: roughly 40% of men are affected at age 40, and over 70% of men are impacted at age 70.

Market Players Outlook

The major companies serving the global tadalafil market include Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co. Pvt. Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., and others. To enhance their market share, industry participants are adopting various strategies including mergers and acquisitions, new launches, collaborations, and partnerships. For instance, the US Food and Drug Administration has given Alembic Pharmaceuticals NSE -0.06% approval for tadalafil pills, that are used to treat erectile dysfunction. The company's abbreviated new drug application (ANDA) for tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg has been approved by the US Food and Drug Administration (USFDA)

End of Project